Oral formulations of celastrol

Amorphous solid dispersions and liquid formulations of celastrol, prepared via spray drying, enhance stability and solubility in FaSSIF, effectively addressing the challenges of oral administration by improving celastrol's performance in simulated intestinal conditions.

WO2026236503A1PCT designated stage Publication Date: 2026-11-12ERX PHARMACEUTICALS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/027118
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-08
Filing Date
2026-05-07
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

There is a need for effective oral pharmaceutical formulations of celastrol that can be conveniently administered to humans or animals, as existing formulations face challenges in stability and solubility, particularly in simulated intestinal fluid conditions.

Method used

The development of amorphous solid dispersions and liquid formulations comprising celastrol, polymers, and solvents, prepared through spray drying, which enhance stability and solubility in fasted state simulated intestinal fluid (FaSSIF) and withstand accelerated storage conditions.

Benefits of technology

The formulations demonstrate improved stability and solubility in FaSSIF, with reduced impurities and water content, maintaining effectiveness over time, thereby addressing the challenges of celastrol's oral administration.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026027118_12112026_PF_FP_ABST
    Figure US2026027118_12112026_PF_FP_ABST
Patent Text Reader

Abstract

The present disclosure provides pharmaceutical compositions of celastrol. The provided pharmaceutical compositions are useful for oral administration of celastrol, pharmaceutically acceptable salts thereof, and amorphous solid dispersions thereof.
Need to check novelty before this filing date? Find Prior Art

Description

Attorney Docket No.: 045898-510001WOORAL FORMULATIONS OF CELASTROL CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to U.S. Provisional Application No. 63 / 801,960, filed May 8, 2025, the contents of which are hereby incorporated by reference in their entirety for all purposes.FIELD

[0002] This application relates to oral formulations of celastrol.BACKGROUND OF THE DISCLOSURE

[0003] Celastrol, a naturally occurring quinone methide triterpene derived from the Thunder of God Vine, has been identified as a pleiotropic compound showing anti-tumor, antiinflammatory, anti-hypertensive, and anti-diabetic activity in numerous cellular and in vivo models. Moreover, in a recent Harvard study, the herbal extracts of the Thunder of God Vine have been shown to function as an appetite suppressant in rodents and may potentially become the key ingredient in obesity drugs.

[0004] Obesity impacts about 15% of the adult population worldwide and about 40% of adults in the United States. Oral routes of administration are often preferred due to the relative convenience of taking tablets, capsules, or liquid formulations, especially for a large patient population. As such, there exists a need to produce oral pharmaceutical formulations suitable for administration to humans or other animals. The present disclosure addresses these needs and provides related advantages as well.SUMMARY OF THE DISCLOSURE

[0005] In some aspects, provided herein are amorphous solid dispersions and pharmaceutical compositions (e.g., for oral delivery) comprising celastrol.

[0006] In some aspects, provided herein is a liquid formulation comprising:(i) celastrol;(ii) a polymer; andAttorney Docket No.: 045898-510001WO(iii) a solvent.

[0007] In some aspects, provided herein is a method for preparing an amorphous solid dispersion comprising spray drying the liquid formulation.

[0008] In some aspects, provided herein is an amorphous solid dispersion comprising:(i) celastrol; and(ii) a polymer.

[0009] In some aspects, provided herein is a pharmaceutical composition comprising the amorphous solid dispersion.

[0010] In some aspects, provided herein is a pharmaceutical composition comprising:(i) celastrol; and(ii) a polymer.

[0011] In some aspects, provided herein is a pharmaceutical composition comprising:(i) celastrol;(ii) copovidone;(iii) microcrystalline cellulose (MCC);(iv) a 3 : 1 mixture of alpha lactose monohydrate and powdered cellulose;(v) hydroxypropyl cellulose (HPC);(vi) sodium carboxymethyl starch (CMS-Na); and(vii) magnesium stearate.

[0012] In some aspects, provided herein is a pharmaceutical composition comprising:(i) celastrol in an amount of from about 0.5 wt.% to about 5 wt.% of the total components of the composition, optionally about 4 wt.% of the total components of the composition, optionally in an amount of about 2 wt.% of the total components of the composition;(ii) copovidone in an amount of from about 2 wt.% to about 10 wt.% of the total components of the composition, optionally about 6 wt.% of the total components of the composition;Attorney Docket No.: 045898-510001WO(iii) microcrystalline cellulose (MCC) in an amount of from about 60 wt.% to about 75% of the total components of the composition, optionally about 67 wt.% of the total components of the composition;(iv) a 3 : 1 mixture of alpha lactose monohydrate and powdered cellulose in an amount of from about 10 wt.% to about 25 wt.% of the total components of the composition, optionally about 17 wt.% of the total components of the composition;(v) hydroxypropyl cellulose (HPC) in an amount of from about 0.5 wt.% to about 5% of the total components of the composition, optionally about 2% of the total components of the composition;(vi) sodium carboxymethyl starch (CMS-Na) in an amount of from about 0.5 wt.% to about 10% of the total components of the composition, optionally about 5% of the total components of the composition; and(vii) magnesium stearate in an amount of from about 0.5 wt.% to about 5 wt.% of the total components of the composition.

[0013] In some aspects, provided herein is a pharmaceutical composition comprising:(i) celastrol in an amount of about 2 wt.% of the total components of the composition; (ii) copovidone in an amount of from about 6 wt.% of the total components of the composition;(iii) microcrystalline cellulose (MCC) in an amount of about 67 wt.% of the total components of the composition;(iv) a 3 : 1 mixture of alpha lactose monohydrate and powdered cellulose in an amount of about 17 wt.% of the total components of the composition;(v) hydroxypropyl cellulose (HPC) in an amount of about 2% of the total components of the composition;(vi) sodium carboxymethyl starch (CMS-Na) in an amount of about 5% of the total components of the composition; and(vii) magnesium stearate in an amount of about 1 wt.% of the total components of the composition.

[0014] In some aspects, provided herein is a pharmaceutical composition comprising:(i) celastrol in an amount of about 4 wt.% of the total components of the composition;Attorney Docket No.: 045898-510001WO(ii) copovidone in an amount of from about 6 wt.% of the total components of the composition;(iii) microcrystalline cellulose (MCC) in an amount of about 67 wt.% of the total components of the composition;(iv) a 3 : 1 mixture of alpha lactose monohydrate and powdered cellulose in an amount of about 17 wt.% of the total components of the composition;(v) hydroxypropyl cellulose (HPC) in an amount of about 2% of the total components of the composition;(vi) sodium carboxymethyl starch (CMS-Na) in an amount of about 5% of the total components of the composition; and(vii) magnesium stearate in an amount of about 1 wt.% of the total components of the composition.

[0015] In some aspects, provided herein is a process for making a pharmaceutical composition comprising celastrol comprising:Step a): Mixing a polymorph of celastrol with a solvent to yield mixture 1;Step b): Adding a polymer to mixture 1 to yield mixture 2; andStep c): Spray-drying mixture 2 to yield an amorphous solid dispersion.

[0016] In some aspects, provided herein is a process for making a pharmaceutical composition comprising celastrol comprising:Step a’): Mixing a polymorph of celastrol and a polymer with a solvent to yield mixture la; andStep b’): Spray-drying mixture la to yield an amorphous solid dispersion.DRAWINGS

[0017] FIG. 1 is an XRPD spectrum of crystalline Form III of celastrol.DETAILED DESCRIPTIONDefinitions

[0018] As used herein, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise. It is further noted that the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basisAttorney Docket No.: 045898-510001WOfor use of such exclusive terminology such as “solely,” “only” and the like in connection with the recitation of claim elements, or use of a “negative” limitation.

[0019] The term “about” refers to being within a range of normal tolerance in the art, for example within 2 standard deviations of the mean. “About” can be understood as within 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, 0.05%, or 0.01% of the stated value. Unless otherwise clear from the context, all numerical values provided herein are modified by the term “about.”

[0020] The terms “crystalline form”, “single crystalline form” and “polymorph” are synonymous and refer to a solid form having a highly regular chemical structure. A crystalline form can have distinguishing, characteristic properties (e.g., XRPD data or thermal data such as DSC and TGA profiles). The term “polymorph” also includes pseudo-polymorphs, which are typically different solvates of a material, and thus their properties differ from one another. Thus, each distinct polymorph and pseudo-polymorph described herein is considered to be a distinct single crystalline form herein.

[0021] As used herein, the term “salt” refers to ionic compounds that result from the neutralization reaction of an acid and a base. They are composed of related numbers of cations (positively charged ions) and anions (negative ions) so that the product is electrically neutral (without a net charge). These component ions can be inorganic, such as chloride (C1-), or organic, such as acetate (C2H3O2-); and can be monatomic, such as fluoride (F-), or polyatomic, such as sulfate (SCh2-).

[0022] The terms “administration”, “administer” and the like, as they apply to, for example, a patient, cell, tissue, organ, or biological fluid, refer to contact of, for example, a pharmaceutical agent or a pharmaceutical composition comprising same, to the patient, cell, tissue, organ, or biological fluid. In the context of a cell, administration includes contact (e.g., in vitro or ex vivo) of a reagent to the cell, as well as contact of a reagent to a fluid, where the fluid is in contact with the cell.Pharmaceutical compositions

[0023] The present disclosure provides liquid formulations, amorphous solid dispersions, and pharmaceutical compositions comprising celastrol (3-hydroxy-9p,13a-dimethyl-2-oxo-24,25,26-trinoroleana-l(10),3,5,7-tetraen-29-oic acid), or a pharmaceutically acceptable salt or polymorph thereof. Celastrol has the chemical formula:Attorney Docket No.: 045898-510001WO\XoHL HO"'(celastrol).

[0024] In some embodiments, a liquid formulation of the disclosure comprises:(i) celastrol;(ii) a polymer; and(iii) a solvent.

[0025] In some embodiments, the solvent is an alcohol. In some embodiments, the solvent is methanol. In some embodiments, the solvent is acetone.

[0026] In some embodiments, the concentration of celastrol in the liquid formulation is from about 10 mg / mL to about 20 mg / mL. In some embodiments, the concentration of celastrol in the liquid formulation is about 15 mg / mL.

[0027] In some embodiments, the concentration of the polymer in the liquid formulation is from about 30 mg / mL to about 70 mg / mL. In some embodiments, the concentration of the polymer in the liquid formulation is from about 40 mg / mL to about 50 mg / mL. In some embodiments, the concentration of the polymer in the liquid formulation is about 45 mg / mL.

[0028] In some embodiments, the concentration of the polymer in the liquid formulation is from about 50 mg / mL to about 70 mg / mL. In some embodiments, the concentration of the polymer in the liquid formulation is from about 55 mg / mL to about 65 mg / mL. In some embodiments, the concentration of the polymer in the liquid formation is about 60 mg / mL.

[0029] In some embodiments, the liquid formulation is for preparing an amorphous solid dispersion. In some embodiments, the liquid formulation is for preparing an amorphous solid dispersion by spray drying the liquid formulation.

[0030] In some embodiments, a method for preparing an amorphous solid dispersion comprises spraying the liquid formulation.

[0031] In some embodiments, an amorphous solid dispersion of the disclosure comprises:(i) celastrol; andAttorney Docket No.: 045898-510001WO(ii) a polymer.

[0032] In some embodiments, the amorphous solid dispersion is made by spray drying a liquid formulation comprising celastrol, a polymer, and a solvent.

[0033] In some embodiments, the liquid formulation or amorphous solid dispersion comprises the celastrol and the polymer at a wt / wt ratio of from about 1 :5 to about 1 : 1. In some embodiments, the liquid formulation or amorphous solid dispersion comprises the celastrol and the polymer at a wt / wt ratio of about 1:3.

[0034] In some embodiments of the liquid formulation or amorphous solid dispersion, the polymer is hydroxypropyl methylcellulose acetate succinate (HPMCAS). In some embodiments of the liquid formulation or amorphous solid dispersion, the polymer is a water-soluble polymer. In some embodiments of the liquid formulation or amorphous solid dispersion, the water-soluble polymer is hydroxypropyl methylcellulose phthalate (HPMCP).

[0035] In some embodiments, the water-soluble polymer comprises l-vinyl-2-pyrrolidone monomers. In some embodiments, l-vinyl-2-pyrrolidone is also referred to as “N-vinylpyrrolidone”. In some embodiments, the water-soluble polymer comprises l-vinyl-2-pyrrolidone monomers and vinyl acetate monomers.

[0036] In some embodiments, the water-soluble polymer is copovidone. Covidone is a copolymer of l-vinyl-2-pyrrolidone and vinyl acetate in a ratio of 6:4 by mass; PVP-VA64®. Copovidone can be described by the following exemplary structure:where m and n are integers.

[0037] In some embodiments, an amorphous solid dispersion comprising copovidone (i.e., an amorphous solid dispersion made by spray drying a liquid formulation comprising copovidone) is more stable in copovidone in fasted state simulated intestinal fluid (FaSSIF) than an amorphous solid dispersion comprising another polymer (i.e., an amorphous solid dispersion made by spray drying a liquid formulation comprising another polymer). For example, in some embodiments, a solution of an amorphous solid dispersion comprising copovidone in FaSSIF has less than 0.5% impurities, less than 0.4% impurities or less than 0.3% impurities (e.g. from degradants). In some embodiments, as demonstrated in Example 3, a solution of an amorphous solid dispersion comprising copovidone in FaSSIF has about 0.25%Attorney Docket No.: 045898-510001WOimpurities. Without wishing to be bound by theory, this indicates a low level of degradation of the components of an amorphous solid dispersion comprising copovidone in FaSSIF.

[0038] In some embodiments, an amorphous solid dispersion comprising copovidone (i.e., an amorphous solid dispersion made by spray drying a liquid formulation comprising copovidone) is more stable under accelerated conditions than an amorphous solid dispersion comprising another polymer (i.e., an amorphous solid dispersion made by spray drying a liquid formulation comprising another polymer). In some embodiments, an amorphous solid dispersion comprising copovidone (i.e., an amorphous solid dispersion made by spray drying a liquid formulation comprising copovidone) has fewer impurities and / or lower water content than an amorphous solid dispersion comprising povidone (i.e., an amorphous solid dispersion made by spray drying a liquid formulation comprising povidone) after being stored at a temperature of about 40 °C ± 2 °C and at a relative humidity of about 75% ± 5% for 10 days or 28 days. For example, in some embodiments, an amorphous solid dispersion comprising copovidone (i.e., an amorphous solid dispersion made by spray drying a liquid formulation comprising copovidone) has about 0.1% or less of total impurities (e.g., about 0.05% or less total impurities) after being stored at a temperature of about 40 °C ± 2 °C and at a relative humidity of about 75% ± 5% for 10 days or 28 days. Further, in some embodiments, an amorphous solid dispersion comprising copovidone (i.e., an amorphous solid dispersion made by spray drying a liquid formulation comprising copovidone) has a water content of about 5% or less (e.g., about 4% or less) after being stored at a temperature of about 40 °C ± 2 °C and at a relative humidity of about 75% ± 5% for 10 days or 28 days. As demonstrated in Example 3, an amorphous solid dispersion comprising copovidone (i.e., an amorphous solid dispersion made by spray drying a liquid formulation comprising copovidone) had about 0.05% total impurities and a water content of about 3% after being stored at a temperature of about 40 °C ± 2 °C and at a relative humidity of about 75% ± 5% for 10 days and about 0.11% total impurities and a water content of about 4% after being stored at a temperature of about 40 °C ± 2 °C and at a relative humidity of about 75% ± 5% for 28 days.

[0039] In some embodiments, an amorphous solid dispersion comprising copovidone (i.e., an amorphous solid dispersion made by spray drying a liquid formulation comprising copovidone) has higher solubility in fasted state simulated intestinal fluid (FaSSIF) than celastrol, or an amorphous solid dispersion comprising another polymer (i.e., an amorphous solid dispersion made by spray drying a liquid formulation comprising another polymer). In some embodiments, the solubility of amorphous solid dispersion comprising copovidone inAttorney Docket No.: 045898-510001WOFaSSIF is from about 0.05 mg / mL to about 0.6 mg / mL (e.g., from about 0.1 mg / mL to about 0.5 mg / mL). In some embodiments, the solubility of amorphous solid dispersion comprising copovidone in FaSSIF is from about 0.3 mg / mL to about 0.7 mg / mL (e.g., about 0.3 mg / mL, about 0.4 mg / mL, about 0.5 mg / mL, about 0.6 mg / mL, or about 0.7 mg / mL). For example, in some embodiments, the solubility of amorphous solid dispersion comprising copovidone in FaSSIF is about 0.1 mg / mL after 0.5h, about 0.3 mg / mL after Ih, and about 0.5 mg / mL after 2h. As demonstrated in Example 3, solutions of an amorphous solid dispersion comprising copovidone (i.e., an amorphous solid dispersion made by spray drying a liquid formulation comprising copovidone) in FaSSIF achieved concentrations of about 0.13 mg / mL after 0.5h, about 0.33 mg / mL after Ih, and about 0.49 mg / mL after 2h. Further, in some embodiments, storage under accelerated conditions (a temperature of about 40 °C ± 2 °C and at a relative humidity of about 75% ± 5%) for 10 or 28 days does not negatively impact the solubility of an amorphous dispersion comprising copovidone in FaSSIF. As demonstrated in Example 3, solutions of an amorphous solid dispersion comprising copovidone (i.e., an amorphous solid dispersion made by spray drying a liquid formulation comprising copovidone) in FaSSIF achieved concentrations of about 0.49 mg / mL after 0.5h, about 0.84 mg / mL after Ih, and about 0.97 mg / mL after 2h, while after storage for 10 days, the solutions achieved concentrations of about 0.25 mg / mL after 0.5h, about 0.63 mg / mL after Ih, and about 0.86 mg / mL after 2h, and after storage for 28 days, the solutions achieved concentrations of 0.21 mg / mL after 0.5h, about 0.61 mg / mL after 1, and about 0.96 mg / mL after 2h.

[0040] In some embodiments, the water-soluble polymer is povidone. In some embodiments, povidone is also referred to as “polyvidone”, “polyvinylpyrrolidone”, or “PVP-K30®”.Povidone can be described by the following exemplary structure:n, where n is an integer.

[0041] In some embodiments, an amorphous solid dispersion comprising povidone (i.e., an amorphous solid dispersion made by spray drying a liquid formulation comprising povidone) is more stable in povidone in fasted state simulated intestinal fluid (FaSSIF) than an amorphous solid dispersion comprising another polymer (i.e., an amorphous solid dispersion made by spray drying a liquid formulation comprising another polymer). For example, in some embodiments, a solution of an amorphous solid dispersion comprising povidone in FaSSIF hasAttorney Docket No.: 045898-510001WOless than 0.5% impurities, less than 0.4% impurities or less than 0.3% impurities (e.g. from degradants). In some embodiments, as demonstrated in Example 3, a solution of an amorphous solid dispersion comprising povidone in FaSSIF has about 0.27% impurities. Without wishing to be bound by theory, this indicates a low level of degradation of the components of an amorphous solid dispersion comprising povidone in FaSSIF.

[0042] In some embodiments, an amorphous solid dispersion comprising povidone (i.e., an amorphous solid dispersion made by spray drying a liquid formulation comprising povidone) is more stable under accelerated conditions than an amorphous solid dispersion comprising another polymer (i.e., an amorphous solid dispersion made by spray drying a liquid formulation comprising another polymer). In some embodiments, an amorphous solid dispersion comprising povidone (i.e., an amorphous solid dispersion made by spray drying a liquid formulation comprising povidone) has fewer impurities and / or lower water content than an amorphous solid dispersion comprising povidone (i.e., an amorphous solid dispersion made by spray drying a liquid formulation comprising povidone) after being stored at a temperature of about 40 °C ± 2 °C and at a relative humidity of about 75% ± 5% for 10 days or 28 days. For example, in some embodiments, an amorphous solid dispersion comprising povidone (i.e., an amorphous solid dispersion made by spray drying a liquid formulation comprising povidone) has about 0.5% or less of total impurities (e.g., about 0.4% or less total impurities or about 0.3% or less total impurities) after being stored at a temperature of about 40 °C ± 2 °C and at a relative humidity of about 75% ± 5% for 10 days or 28 days. Further, in some embodiments, an amorphous solid dispersion comprising povidone (i.e., an amorphous solid dispersion made by spray drying a liquid formulation comprising povidone) has a water content of about 6% or less (e.g., about 5% or less) after being stored at a temperature of about 40 °C ± 2 °C and at a relative humidity of about 75% ± 5% for 10 days or 28 days. As demonstrated in Example 3, an amorphous solid dispersion comprising povidone (i.e., an amorphous solid dispersion made by spray drying a liquid formulation comprising povidone) had about 0.2% total impurities and a water content of about 5% after being stored at a temperature of about 40 °C ± 2 °C and at a relative humidity of about 75% ± 5% for 10 days and about 0.4% total impurities and a water content of about 6% after being stored at a temperature of about 40 °C ± 2 °C and at a relative humidity of about 75% ± 5% for 28 days.

[0043] In some embodiments, an amorphous solid dispersion comprising povidone (i.e., an amorphous solid dispersion made by spray drying a liquid formulation comprising povidone) has higher solubility in fasted state simulated intestinal fluid (FaSSIF) than celastrol, or anAttorney Docket No.: 045898-510001WOamorphous solid dispersion comprising another polymer (i.e., an amorphous solid dispersion made by spray drying a liquid formulation comprising another polymer). In some embodiments, the solubility of amorphous solid dispersion comprising povidone in FaSSIF is from about 0.2 mg / mL to about 0.7 mg / mL (e.g., from about 0.3 mg / mL to about 0.6 mg / mL). In some embodiments, the solubility of amorphous solid dispersion comprising povidone in FaSSIF is from about 0.3 mg / mL to about 0.8 mg / mL (e.g., about 0.3 mg / mL, about 0.4 mg / mL, about 0.5 mg / mL, about 0.6 mg / mL, about 0.7 mg / mL, or about 0.8 mg / mL). For example, in some embodiments, the solubility of amorphous solid dispersion comprising povidone in FaSSIF is about 0.3 mg / mL after 0.5h, about 0.5 mg / mL after Ih, and about 0.6 mg / mL after 2h. As demonstrated in Example 3, solutions of an amorphous solid dispersion comprising povidone (i.e., an amorphous solid dispersion made by spray drying a liquid formulation comprising povidone) in FaSSIF achieved concentrations of about 0.28 mg / mL after 0.5h, about 0.47 mg / mL after Ih, and about 0.64 mg / mL after 2h. Further, in some embodiments, storage under accelerated conditions (a temperature of about 40 °C ± 2 °C and at a relative humidity of about 75% ± 5%) for 10 or 28 days does not negatively impact the solubility of an amorphous dispersion comprising povidone in FaSSIF. As demonstrated in Example 3, solutions of an amorphous solid dispersion comprising povidone (i.e., an amorphous solid dispersion made by spray drying a liquid formulation comprising povidone) in FaSSIF achieved concentrations of about 0.63 mg / mL after 0.5h, about 0.88 mg / mL after Ih, and about 1.02 mg / mL after 2h, while after storage for 10 days, the solutions achieved concentrations of about 0.40 mg / mL after 0.5h, about 0.48 mg / mL after Ih, and about 0.58 mg / mL after 2h, and after storage for 28 days, the solutions achieved concentrations of 0.22 mg / mL after 0.5h, about 0.82 mg / mL after 1, and about 1.07 mg / mL after 2h.

[0044] In some embodiments, the water-soluble polymer comprises caprolactam monomers, polyvinyl acetate monomers, and polyethylene glycol monomers. In some embodiments, the water-soluble polymer is a polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer. For example, in some embodiments, the water-soluble polymer is a polymer comprising polyethylene glycol 6000 (PEG 6000), vinylcaprolactam and vinyl acetate at a wt. / wt. / wt. ratio of about 13:57:30 (i.e., Soluplus®). In some embodiments, the water-soluble polymer comprises polyethylene glycol 6000 (PEG 6000), vinylcaprolactam and vinyl acetate at a wt. / wt. / wt. ratio of about 13:57:30.

[0045] In some embodiments, an amorphous solid dispersion comprising a polymer comprising polyethylene glycol 6000 (PEG 6000), vinylcaprolactam and vinyl acetate at aAttorney Docket No.: 045898-510001WOwt. / wt. / wt. ratio of about 13:57:30 (i.e., Soluplus®) (i.e., an amorphous solid dispersion made by spray drying a liquid formulation comprising a polymer comprising polyethylene glycol 6000 (PEG 6000), vinylcaprolactam and vinyl acetate at a wt. / wt. / wt. ratio of about 13:57:30 (i.e., Soluplus®)) is more stable in a polymer comprising polyethylene glycol 6000 (PEG 6000), vinylcaprolactam and vinyl acetate at a wt. / wt. / wt. ratio of about 13:57:30 (i.e., Soluplus®) in fasted state simulated intestinal fluid (FaSSIF) than an amorphous solid dispersion comprising another polymer (i.e., an amorphous solid dispersion made by spray drying a liquid formulation comprising another polymer). For example, in some embodiments, a solution of an amorphous solid dispersion comprising a polymer comprising polyethylene glycol 6000 (PEG 6000), vinylcaprolactam and vinyl acetate at a wt. / wt. / wt. ratio of about 13:57:30 (i.e., Soluplus®) in FaSSIF has less than 0.5% impurities, less than 0.4% impurities or less than 0.3% impurities (e.g. from degradants). In some embodiments, as demonstrated in Example 3, a solution of an amorphous solid dispersion comprising a polymer comprising polyethylene glycol 6000 (PEG 6000), vinylcaprolactam and vinyl acetate at a wt. / wt. / wt. ratio of about 13:57:30 (i.e., Soluplus®) in FaSSIF has about 0.20% impurities. Without wishing to be bound by theory, this indicates a low level of degradation of the components of an amorphous solid dispersion comprising a polymer comprising polyethylene glycol 6000 (PEG 6000), vinylcaprolactam and vinyl acetate at a wt. / wt. / wt. ratio of about 13:57:30 (i.e., Soluplus®) in FaSSIF.

[0046] In some embodiments, the water-soluble polymer comprises acrylic acid monomers. In some embodiments, wherein the water-soluble polymer is a polymethacrylate. In some embodiments, the water-soluble polymer is a co-polymer comprising methacrylic acid monomers and methyl methacrylate monomers at a monomer ratio of about 1:2 (i.e., EUDRAGIT®). In some embodiments, the water-soluble polymer is an anionic co-polymer comprising methacrylic acid monomers and methyl methacrylate monomers at a monomer ratio of about 1:1 (i.e., EUDRAGIT -L 100®). In some embodiments, the water-soluble polymer is a poly(methacrylic acid-co-methyl methacrylate). In some embodiments, the co-polymer comprising methacrylic acid monomers and methyl methacrylate monomers can be describedby the following structure:, where m and n are integers.

[0047] In some embodiments, a pharmaceutical composition of the disclosure comprises:(i) celastrol;Attorney Docket No.: 045898-510001WO(ii) copovidone;(iii) microcrystalline cellulose (MCC);(iv) a 3 : 1 mixture of alpha lactose monohydrate and powdered cellulose;(v) hydroxypropyl cellulose (HPC);(vi) sodium carboxymethyl starch (CMS-Na); and(vii) magnesium stearate.

[0048] In some embodiments, celastrol is present in an amount of from about 0.5 wt.% to about 5 wt.% of the total components of the composition. In some embodiments, celastrol is present in an amount of about 4 wt.% of the total components of the composition. In some embodiments, celastrol is present in an amount of about 2 wt.% of the total components of the composition.

[0049] In some embodiments, the polymer is hydroxypropyl methylcellulose acetate succinate (HPMCAS, e.g. HPMCAS-LG). In some embodiments, an amorphous solid dispersion comprising HPMCAS (i.e., an amorphous solid dispersion made by spray drying a liquid formulation comprising HPMCAS) is more stable in HPMCAS in fasted state simulated intestinal fluid (FaSSIF) than an amorphous solid dispersion comprising another polymer (i.e., an amorphous solid dispersion made by spray drying a liquid formulation comprising another polymer). For example, in some embodiments, a solution of an amorphous solid dispersion comprising HPMCAS in FaSSIF has less than 0.5% impurities, less than 0.4% impurities or less than 0.3% impurities (e.g. from degradants). In some embodiments, as demonstrated in Example 3, a solution of an amorphous solid dispersion comprising HPMCAS in FaSSIF has about 0.25% impurities. Without wishing to be bound by theory, this indicates a low level of degradation of the components of an amorphous solid dispersion comprising HPMCAS in FaSSIF.

[0050] In some embodiments, an amorphous solid dispersion comprising HPMCAS (i.e., an amorphous solid dispersion made by spray drying a liquid formulation comprising HPMCAS) is more stable under accelerated conditions than an amorphous solid dispersion comprising another polymer (i.e., an amorphous solid dispersion made by spray drying a liquid formulation comprising another polymer). In some embodiments, an amorphous solid dispersion comprising HPMCAS (i.e., an amorphous solid dispersion made by spray drying a liquid formulation comprising HPMCAS) has fewer impurities and / or lower water content than anAttorney Docket No.: 045898-510001WOamorphous solid dispersion comprising HPMCAS (i.e., an amorphous solid dispersion made by spray drying a liquid formulation comprising HPMCAS) after being stored at a temperature of about 40 °C ± 2 °C and at a relative humidity of about 75% ± 5% for 10 days or 28 days. For example, in some embodiments, an amorphous solid dispersion comprising HPMCAS (i.e., an amorphous solid dispersion made by spray drying a liquid formulation comprising HPMCAS) has about 1.5 % or less of total impurities (e.g., about 1% or less total impurities or about 0.5% or less total impurities) after being stored at a temperature of about 40 °C ± 2 °C and at a relative humidity of about 75% ± 5% for 10 days or 28 days. Further, in some embodiments, an amorphous solid dispersion comprising HPMCAS (i.e., an amorphous solid dispersion made by spray drying a liquid formulation comprising HPMCAS) has a water content of about 2% or less (e.g., about 1.5% or less) after being stored at a temperature of about 40 °C ± 2 °C and at a relative humidity of about 75% ± 5% for 10 days or 28 days. As demonstrated in Example 3, an amorphous solid dispersion comprising HPMCAS (i.e., an amorphous solid dispersion made by spray drying a liquid formulation comprising HPMCAS) had about 0.5% total impurities and a water content of about 1.5% after being stored at a temperature of about 40 °C ± 2 °C and at a relative humidity of about 75% ± 5% for 10 days and about 1.3% total impurities and a water content of about 2% after being stored at a temperature of about 40 °C ± 2 °C and at a relative humidity of about 75% ± 5% for 28 days.

[0051] In some embodiments, an amorphous solid dispersion comprising HPMCAS (i.e., an amorphous solid dispersion made by spray drying a liquid formulation comprising HPMCAS) has higher solubility in fasted state simulated intestinal fluid (FaSSIF) than celastrol, or an amorphous solid dispersion comprising another polymer (i.e., an amorphous solid dispersion made by spray drying a liquid formulation comprising another polymer). In some embodiments, the solubility of amorphous solid dispersion comprising HPMCAS in FaSSIF is from about 0.2 mg / mL to about 0.7 mg / mL (e.g., from about 0.3 mg / mL to about 0.6 mg / mL). In some embodiments, the solubility of amorphous solid dispersion comprising HPMCAS in FaSSIF is from about 0.3 mg / mL to about 0.8 mg / mL (e.g., about 0.3 mg / mL, about 0.4 mg / mL, about 0.5 mg / mL, about 0.6 mg / mL, about 0.7 mg / mL, or about 0.8 mg / mL). For example, in some embodiments, the solubility of amorphous solid dispersion comprising HPMCAS in FaSSIF is about 0.3 mg / mL after 0.5h, about 0.5 mg / mL after Ih, and about 0.6 mg / mL after 2h. As demonstrated in Example 3, solutions of an amorphous solid dispersion comprising HPMCAS (i.e., an amorphous solid dispersion made by spray drying a liquid formulationAttorney Docket No.: 045898-510001WOcomprising HPMCAS) in FaSSIF achieved concentrations of about 0.22 mg / mL after 0.5h, about 0.52 mg / mL after Ih, and about 0.70 mg / mL after 2h.

[0052] Further, in some embodiments, storage under accelerated conditions (a temperature of about 40 °C ± 2 °C and at a relative humidity of about 75% ± 5%) for 10 or 28 days does not negatively impact the solubility of an amorphous dispersion comprising HPMCAS in FaSSIF. As demonstrated in Example 3, solutions of an amorphous solid dispersion comprising HPMCAS in FaSSIF achieved concentrations of about 0.32 mg / mL after 0.5h, about 0.88 mg / mL after Ih, and about 1.03 mg / mL after 2h, while after storage for 10 days, the solutions achieved concentrations of about 0.63 mg / mL after 0.5h, about 0.80 mg / mL after Ih, and about 0.87 mg / mL after 2h, and after storage for 28 days, the solutions achieved concentrations of 0.40 mg / mL after 0.5h, about 0.93 mg / mL after 1, and about 1.13 mg / mL after 2h.

[0053] In some embodiments, the polymer is a water-soluble polymer. In some embodiments, the water-soluble polymer is hydroxypropyl methylcellulose phthalate (HPMCP). In some embodiments, the water-soluble polymer comprises l-vinyl-2-pyrrolidone monomers. In some embodiments, the water-soluble polymer comprises l-vinyl-2-pyrrolidone monomers and vinyl acetate monomers. In some embodiments, the water-soluble polymer is copovidone. In some embodiments, the water-soluble polymer is povidone. In some embodiments, the water-soluble polymer comprises caprolactam monomers, polyvinyl acetate monomers, and polyethylene glycol monomers. In some embodiments, the water-soluble polymer is a polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer. In some embodiments, the water-soluble polymer comprises polyethylene glycol 6000 (PEG 6000), vinylcaprolactam and vinyl acetate at a wt. / wt. / wt. ratio of about 13:57:30. In some embodiments, the water-soluble polymer comprises acrylic acid monomers. In some embodiments, wherein the water-soluble polymer is a polymethacrylate. In some embodiments, the water-soluble polymer is a co-polymer comprising methacrylic acid monomers and methyl methacrylate monomers at a monomer ratio of about 1:2. In some embodiments, the water-soluble polymer is an anionic co-polymer comprising methacrylic acid monomers and methyl methacrylate monomers at a monomer ratio of about 1:1. In some embodiments, the water-soluble polymer is a poly(methacrylic acid-co-methyl methacrylate). In some embodiments, the pharmaceutical composition comprises the polymer in an amount of from about 2 wt.% to about 10 wt.% of the total components of the composition. In someAttorney Docket No.: 045898-510001WOembodiments, the pharmaceutical composition comprises the polymer in an amount of about 6 wt.% of the total components of the composition.

[0054] In some embodiments, the pharmaceutical composition further comprises a filler. In some embodiments, the pharmaceutical composition comprises the filler in an amount of from about 75 wt.% to about 85 wt.% of the total components of the composition. In some embodiments, the pharmaceutical composition comprises the filler in an amount of from about 80 wt.% to about 90 wt.% of the total components of the composition. In some embodiments, the pharmaceutical composition comprises the filler in an amount of about 84 wt.% of the total components of the composition.

[0055] In some embodiments, the filler is selected from one or more of microcrystalline cellulose (MCC), a mixture of alpha lactose monohydrate and powdered cellulose, and mannitol. In some embodiments, the filler comprises microcrystalline cellulose (MCC). In some embodiments, the pharmaceutical composition comprises microcrystalline cellulose (MCC) in an amount of from about 60 wt.% to about 75% of the total components of the composition. In some embodiments, the pharmaceutical composition comprises microcrystalline cellulose (MCC) in an amount of about 67 wt.% of the total components of the composition.

[0056] In some embodiments, the filler comprises a mixture of alpha lactose monohydrate and powdered cellulose. In some embodiments, the filler comprises a mixture of alpha lactose monohydrate and powdered cellulose at a ratio of about 3:1. In some embodiments, the pharmaceutical composition comprises the mixture of alpha lactose monohydrate and powdered cellulose in an amount of from about 10 wt.% to about 25 wt.% of the total components of the composition. In some embodiments, the pharmaceutical composition comprises the mixture of alpha lactose monohydrate and powdered cellulose in an amount of about 17 wt.% of the total components of the composition. In some embodiments, the filler comprises microcrystalline cellulose (MCC) and a mixture of alpha lactose monohydrate and powdered cellulose.

[0057] In some embodiments, the pharmaceutical composition further comprises a binder. In some embodiments, the binder is hydroxypropyl cellulose (HPC). In some embodiments, the pharmaceutical composition comprises the binder in an amount of from about 0.5 wt.% to about 5% of the total components of the composition. In some embodiments, the pharmaceuticalAttorney Docket No.: 045898-510001WOcomposition comprises the binder in an amount of about 2 wt.% of the total components of the composition.

[0058] In some embodiments, the pharmaceutical composition further comprises a disintegrant. In some embodiments, the disintegrant comprises one or more of sodium starch glycolate (SSG), sodium carboxymethyl starch (CMS-Na), or polyvinylpolypyrrolidone (crospovidone). In some embodiments, the disintegrant is polyvinylpolypyrrolidone (crospovidone). In some embodiments, the disintegrant is sodium starch glycolate (SSG). In some embodiments, the disintegrant is sodium carboxymethyl starch (CMS-Na). In some embodiments, the pharmaceutical composition comprises the disintegrant in an amount of from about 0.5 wt.% to about 10% of the total components of the composition. In some embodiments, the pharmaceutical composition comprises the disintegrant in an amount of from about 2 wt.% to about 8% of the total components of the composition. In some embodiments, the pharmaceutical composition comprises the disintegrant in an amount of about 5 wt.% of the total components of the composition.

[0059] In some embodiments, the pharmaceutical composition further comprises a lubricant. In some embodiments, the lubricant is sodium stearyl fumarate. In some embodiments, the lubricant is magnesium stearate. In some embodiments, the pharmaceutical composition comprises the lubricant in an amount of from about 0.5 wt.% to about 5 wt.% of the total components of the composition. In some embodiments, the pharmaceutical composition comprises the lubricant in an amount of from about 0.5 wt.% to about 3 wt.% of the total components of the composition. In some embodiments, the pharmaceutical composition comprises the lubricant in an amount of about 1 wt.% of the total components of the composition.

[0060] In some embodiments, a pharmaceutical composition of the disclosure comprises:(i) celastrol in an amount of from about 0.5 wt.% to about 5 wt.% of the total components of the composition, optionally about 4 wt.% of the total components of the composition, optionally in an amount of about 2 wt.% of the total components of the composition;(ii) copovidone in an amount of from about 2 wt.% to about 10 wt.% of the total components of the composition, optionally about 6 wt.% of the total components of the composition;Attorney Docket No.: 045898-510001WO(iii) microcrystalline cellulose (MCC) in an amount of from about 60 wt.% to about 75% of the total components of the composition, optionally about 67 wt.% of the total components of the composition;(iv) a 3 : 1 mixture of alpha lactose monohydrate and powdered cellulose in an amount of from about 10 wt.% to about 25 wt.% of the total components of the composition, optionally about 17 wt.% of the total components of the composition;(v) hydroxypropyl cellulose (HPC) in an amount of from about 0.5 wt.% to about 5% of the total components of the composition, optionally about 2% of the total components of the composition;(vi) sodium carboxymethyl starch (CMS-Na) in an amount of from about 0.5 wt.% to about 10% of the total components of the composition, optionally about 5% of the total components of the composition; and(vii) magnesium stearate in an amount of from about 0.5 wt.% to about 5 wt.% of the total components of the composition.

[0061] In some embodiments, the pharmaceutical composition of the disclosure comprises:(i) celastrol in an amount of about 2 wt.% of the total components of the composition; (ii) copovidone in an amount of from about 6 wt.% of the total components of the composition;(iii) microcrystalline cellulose (MCC) in an amount of about 67 wt.% of the total components of the composition;(iv) a 3 : 1 mixture of alpha lactose monohydrate and powdered cellulose in an amount of about 17 wt.% of the total components of the composition;(v) hydroxypropyl cellulose (HPC) in an amount of about 2% of the total components of the composition;(vi) sodium carboxymethyl starch (CMS-Na) in an amount of about 5% of the total components of the composition; and(vii) magnesium stearate in an amount of about 1 wt.% of the total components of the composition.

[0062] In some embodiments, the pharmaceutical composition of the disclosure comprises:Attorney Docket No.: 045898-510001WO(i) celastrol in an amount of about 4 wt.% of the total components of the composition; (ii) copovidone in an amount of from about 6 wt.% of the total components of the composition;(iii) microcrystalline cellulose (MCC) in an amount of about 67 wt.% of the total components of the composition;(iv) a 3 : 1 mixture of alpha lactose monohydrate and powdered cellulose in an amount of about 17 wt.% of the total components of the composition;(v) hydroxypropyl cellulose (HPC) in an amount of about 2% of the total components of the composition;(vi) sodium carboxymethyl starch (CMS-Na) in an amount of about 5% of the total components of the composition; and(vii) magnesium stearate in an amount of about 1 wt.% of the total components of the composition.

[0063] In some embodiments, the pharmaceutical composition is in the form of a tablet. In some embodiments, the tablet comprises celastrol in an amount of about 2 mg. In some embodiments, the tablet comprises celastrol in an amount of about 4 mg. In some embodiments, the tablet has a weight of about 100 mg.

[0064] In some embodiments, the tablet further comprises a film coating. In some embodiments, the coating is a gastric soluble coating. In some embodiments, the coating comprises talc, glyceryl monocaprylocaprate, and polyvinyl alcohol. In some embodiments, the coating comprises hypromellose, lactose monohydrate, titanium dioxide, and polyethylene glycol. In some embodiments, the coating comprises talc, glyceryl monocaprylocaprate, sodium lauryl sulfate, and polyvinyl alcohol. In some embodiments, the coating comprises talc, glyceryl monocaprylocaprate, polyvinyl alcohol graft polymer, titanium dioxide, polyethylene glycol, and polyvinyl alcohol. In some embodiments, the coating comprises partially hydrolyzed polyvinyl alcohol, Glyceryl monocaprylocaprate, Type I, macrogol(PEG) polyvinyl alcohol graft copolymer, titanium dioxide, talc, ferric oxide yellow, and ferrosoferric oxide / black iron oxide. In some embodiments, the coating comprises partially hydrolyzed polyvinyl alcohol, titanium dioxide, talc, ferric oxide yellow, and ferrosoferric oxide / black iron oxide. In some embodiments, the coating comprises hydroxypropyl methyl cellulose,Attorney Docket No.: 045898-510001WOmacrogol(PEG), titanium dioxide, and ferric oxide yellow. In some embodiments, the coating further comprises a pigment. In some embodiments, the coating further comprises Fe(OH)3.

[0065] In some embodiments, the tablet comprises the coating in an amount of from about 3% to about 5% of the total weight of the tablet. In some embodiments, the tablet comprises the coating in an amount of about 4% of the total weight of the tablet. In some embodiments, the tablet comprises the coating in an amount of about 3.8% of the total weight of the tablet. In some embodiments, the total weight of the tablet including the coating is about 104 mg.

[0066] In some embodiments, the tablet is soluble in an aqueous solvent. In some embodiments, the aqueous solvent has a pH of about 7. In some embodiments, the aqueous solvent comprises a sodium phosphate buffer. In some embodiments, the aqueous solvent comprises sodium dodecyl sulfate (SDS).

[0067] In some embodiments, at least 90% of the tablet dissolves within about 20 min. In some embodiments, at least 95% of the tablet dissolves within about 20 min.

[0068] In some embodiments of a liquid formulation, amorphous solid dispersion, or pharmaceutical composition, the celastrol is in amorphous form. In some embodiments, the celastrol is in the form of a polymorph.

[0069] In some embodiments, the process for making a pharmaceutical composition of the disclosure comprises:Step a): Mixing a polymorph of celastrol with a solvent to yield mixture 1;Step b): Adding a polymer to mixture 1 to yield mixture 2; andStep c): Spray-drying mixture 2 to yield an amorphous solid dispersion.

[0070] In some embodiments, the process for making a pharmaceutical composition of the disclosure comprises:Step a’): Mixing a polymorph of celastrol and a polymer with a solvent to yield mixture la; andStep b’): Spray-drying mixture la to yield an amorphous solid dispersion.

[0071] In some embodiments, the solvent is an alcohol. In some embodiments, the alcohol is methanol. In some embodiments, the solvent is acetone. In some embodiments, the polymer is hydroxypropyl methylcellulose acetate succinate (HPMCAS). In some embodiments, the polymer is a water-soluble polymer. In some embodiments, the water-soluble polymer isAttorney Docket No.: 045898-510001WOhydroxypropyl methylcellulose phthalate (HPMCP). In some embodiments, the water-soluble polymer comprises l-vinyl-2-pyrrolidone monomers. In some embodiments, the water-soluble polymer comprises l-vinyl-2-pyrrolidone monomers and vinyl acetate monomers. In some embodiments, the water-soluble polymer is copovidone. In some embodiments, the water-soluble polymer is povidone. In some embodiments, the water-soluble polymer comprises caprolactam monomers, polyvinyl acetate monomers, and polyethylene glycol monomers. In some embodiments, the water-soluble polymer is a polyvinyl caprolactam-polyvinyl acetatepolyethylene glycol graft copolymer. In some embodiments, the water-soluble polymer comprises polyethylene glycol 6000 (PEG 6000), vinylcaprolactam and vinyl acetate at a wt / wt / wt. ratio of about 13:57:30. In some embodiments, the water-soluble polymer comprises acrylic acid monomers. In some embodiments, the water-soluble polymer is a polymethacrylate. In some embodiments, the water-soluble polymer is a co-polymer comprising methacrylic acid monomers and methyl methacrylate monomers at a monomer ratio of about 1:2. In some embodiments, the water-soluble polymer is an anionic co-polymer comprising methacrylic acid monomers and methyl methacrylate monomers at a monomer ratio of about 1:1. In some embodiments, the water-soluble polymer is a poly(methacrylic acid-co-methyl methacrylate).

[0072] In some embodiments of a process, liquid formulation, amorphous solid dispersion or pharmaceutical composition, the polymorph of celastrol is a crystalline Form III of celastrol, wherein the crystalline Form III of celastrol is characterized by an X-ray powder diffraction pattern comprising peaks at 29 angles (±0.2) selected from the group consisting of 9.51°, 14.81°, and 16.84°. In some embodiments, the crystalline Form III of celastrol is characterized by an X-ray powder diffraction pattern further comprising one or more peaks at 29 angles (±0.2) selected from the group consisting of 13.60°, 14.65°, 18.74°, and 19.10°. In some embodiments, the crystalline Form III of celastrol is characterized by an X-ray powder diffraction pattern that is substantially the same as Figure 1.

[0073] In some embodiments, the crystalline Form III of celastrol is characterized by a differential scanning calorimetry (DSC) profile with no endothermic peak and an exothermic peak at about 215 °C (onset). In some embodiments, the crystalline Form III of celastrol is characterized by thermal gravimetric analysis (TGA) profile with about 0.5% weight loss at about the exothermic peak at about 215 °C (onset). In some embodiments, the crystalline Form III of celastrol comprises about 5000 ppm or less of n-heptane. In some embodiments, the crystalline Form III of celastrol comprises about 70 ppm or less of n-heptane. In someAttorney Docket No.: 045898-510001WOembodiments, the crystalline form comprises about 5000 ppm or less of 2-methyltetrahydrofuran. In some embodiments, the crystalline form comprises about 500 ppm or less of 2-methyltetrahydrofuran. In some embodiments, the crystalline form comprises about 5000 ppm or less of ethyl acetate. In some embodiments, the crystalline form comprises about 10 ppm or less of ethyl acetate. In some embodiments, the crystalline Form III of celastrol comprises about 3,000 ppm or less of methanol. In some embodiments, the crystalline Form III of celastrol comprises about 1,500 ppm or less of methanol. In some embodiments, the crystalline Form III of celastrol comprises about 5000 ppm or less of ethanol. In some embodiments, the crystalline Form III of celastrol comprises about 600 ppm or less of ethanol. In some embodiments, the crystalline Form III of celastrol is free of methanol, ethanol, and / or di chloromethane. In some embodiments, the crystalline Form III of celastrol has at least 99.8% purity. In some embodiments, the crystalline Form III of celastrol is anhydrous.EXAMPLES

[0074] A list of abbreviations, acronyms, and common names used in the Examples is presented in Table 1 below.Table 1. Abbreviations, acronyms, and common names.Term Meaning Term MeaningASD Amorphous solid dispersion LDPE Low-density polyethylene AUC Area under the curve MCC Microcrystalline celluose AUCinf_pred Area under the curve extracted Mg-St Magnesium stearateto infinityAUClast Area under the curve from mpk Milligrams per kilogram dosing to time of lastmeasurementAve. Average NA Not availableBHT / BHA Butylated hydroxyanisole / Na-CMS / Sodium carboxymethyl starch butylated hydroxytoluene CMS-NaCellatose 80 A mixture containing 75% PEG Polyethylene glycolalpha-lactose monohydrate and25% powdered celluloseCmax Maximum concentration PK Pharmacokinetic Cremorphor RH40 Peg-40 Hydrogenated Castor Oil PO Per osAttorney Docket No.: 045898-510001WOcv Coefficient of variation Polysorbate 2-[2-[3,4-bis(2- 80 hydroxyethoxy)oxolan-2-yl]-2-(2- hydroxyethoxy)ethoxy] ethyl octadec-9-enoate DCMPSD Particle size distribution Dis. Dissolution PVA Polyvinyl AlcoholEDTA-K2 Dipotassium PVP-K30 Polyvinylpyrrolidone / polyvidone ethylenediaminetetraacetic acid / povidone EUDRAGITL100 A co-polymer comprising R.H. Relative humidity methacrylic acid monomers andmethyl methacrylate monomersat a monomer ratio of about 1 :2FaSSIF Fasted State Simulated Intestinal rpm Rotations per minuteFluidGelucire 44 / 14 Lauroyl polyoxyl / macrogol 32 RSD Relative standard deviation glyceridesgmcc Glycerol monocaprylocaprate SDS Sodium dodecyl sulfate GMDCC Glyceryl Mono andDicaprylocaprateGMCC Type 1 Glycerol monocaprylocaprate SLS Sodium lauryl sulfate mono / diglycerides,glycerolHDPE High density polyethylene Soluplus A polymer comprising polyethylene glycol 6000 (PEG 6000), vinylcaprolactam and vinyl acetate at a wt. / wt. / wt. ratio of about 13:57:30HPC Hydroxypropyl cellulose Solutol HS- 2-hydroxyethyl 12- hydroxyoctadecanoate HPLC High-performance liquid THF Tetrahydrofuran chromatographyHPMC Hydroxypropyl methylcellulose Tmax Time to peak drug concentration HPMCAS-LG Hypromellose Acetate TPGS-1000 D-a-Tocopherol polyethylene Succinate, L-Grade glycol 1000 succinate HPMCP Hydroxypropyl methylcellulose VC palmitate Ascorbyl palmitate phthalateKollidon VA64 / Copovidone VE acetate a-Tocopheryl acetatePVA-VA64Labrafil M 1944CS Oleoyl polyoxyl-6 glycerides w / w% Weight %Attorney Docket No.: 045898-510001WOLabrasol ALF Caprylocaproyl Polyoxyl-8 a-VE a- TocopherolglyceridesExample 1 - Lipid Formulations

[0075] In a first experiment, semi-solid gel capsules were prepared as described in Table 2, below:Table 2: Semi-solid gel capsules comprising celastrolOral suspension 1 mg / g celastrol was suspended in 10 mL of 0.01% Polysorbate 80 Semi-solid gel capsule 1 10 mg / g celastrol in Gelucire 44 / 14Semi-solid gel capsule 2 10 mg / g celastrol in Gelucire 44 / 14 with 0.5% w / w Polysorbate 80

[0076] The semi-solid gel capsules of Table 2 showed improved exposure and decreased variability in dogs as compared with oral suspensions of celastrol. However, these semi-solid gel capsules also showed an increase in impurities over time, indicative of low stability. Thus, a further study was performed to improve the stability of semi-solid capsules. Various vehicles (hydrophilic and lipidic solvents) were screened to obtain a self-microemulsifying drug delivery system with improved stability as compared with semi-solid capsules.

[0077] An excipient base and, in some formulations, an additive were melted at 50 °C and stirred in glass vials for 24 hours. 10 mg / g of celastrol was added, and the solution was stirred at 50 °C for about 30-60 minutes until the celastrol was fully dissolved. About 500 mg of the formulation was pipetted into size #0 gelatin capsules and allowed to solidify at room temperature before capsules were closed by hand. Capsules were placed in 20 ml glass vials with an oxygen scavenger, and the vial headspace was filled with nitrogen. The capsule caps were then removed. The capsule contents were dissolved with 5 ml of methanol for about 15 minutes at 50 °C. The samples prepared with Solutol HS-15 were dissolved with ethanol instead of methanol. 1 ml of each solution was pipetted for HPLC analysis. The sample combinations and process stability results on day 0 are shown in Table 3 below.Attomey Docket No.: 045898-510001WOTable 3. Composition and stability of lipid samples comprising celastrol.Total related Base Additive Amount, w / w Purity (%)substances (%) NA NA 99.39 0.61 Cysteine0.1% 49.84 50.16 hydrochlorideVitamin C0.1% 99.29 0.71 palmitateBHT / BHA 0.05%+0.05% 98.30 1.70 Gelucire 44 / 14Sodium bisulfite 0.1% 51.48 48.52 Sodium0.1% 68.92 31.08 metabisulfiteTocopherol acetate 0.1% 99.19 0.81 a- Tocopherol 0.1% 99.89 0.11 a- Tocopherol, 1% 1% 99.73 0.27 NA NA 99.95 0.05 TPGS-1000a- Tocopherol 0.1% 100.00 0.00 NA NA 99.67 0.33 Vitamin CSolutol HS-15 0.1% 99.88 0.12palmitatea- Tocopherol 0.1% 99.93 0.08 NA NA 99.55 0.45 Vitamin CCremophor RH40 0.1% 99.90 0.10palmitatea- Tocopherol 0.1% 99.91 0.09

[0078] As shown in the table, the highest purities were achieved in formulations using TPGS- 1000 as the excipient base.

[0079] The preferred capsule samples were further investigated under accelerated (40°C / 75%R.H.) and long-term (25°C / 60%R.H.) conditions. At each sampling point, the capsule caps were removed. 5 ml of methanol was added to the glass vial to fully dissolve the capsule content at 50°C for about 15 minutes. The samples prepared with Solutol HS-15 were dissolved with ethanol instead of methanol. 1 ml of each solution was pipetted for HPLC analysis. The sample combinations and stability results under accelerated and long-term conditions are shown in Table 4 and Table 5 below.Attorney Docket No.: 045898-510001WOTable 4. Composition and stability of lipid samples comprising celastrol under accelerated conditions.Total related substances, %Base Additives 25°C / 60%R.H. 40°C / 75%R.H.Initial4w 4w NA 0.61 13.10VC palmitate 0.71 13.76Gelucire 44 / 14 BHT / BHA 1.70 21.72 N.A.VE acetate 0.81 12.87a-VE, 0.1% 0.11 12.29TPGS-1000 NA 0.05 0.06 0.07NA 0.33 0.63 3.68 Solutol HS-15VC palmitate 0.12 0.17 0.40 NA 0.45 0.93 4.28 Cremorphor RH40VC palmitate 0.10 0.63 1.80 Table 5. Composition and stability of lipid samples comprising celastrol under accelerated conditions.Total related substances, %Base Additives 25°C / 60%R.H. 40°C / 75%R.H.Initial18 days 4w 18 days 4w Gelucire 44 / 14 a-VE, 1% 0.27 8.26 11.99 N.A.TPGS-1000 a-VE, 0.1% 0.06 0.07 0.10 0.07 0.07 Solutol HS-15 a-VE, 0.1% 0.08 0.58 0.69 1.98 2.95Cremophor RH40 a-VE, 0.1% 0.09 0.57 0.72 2.44 2.50

[0080] Of the tested formulations, only formulations using TPGS-1000 as the excipient base appeared to have acceptable long-term stability performance at room temperature.

[0081] Additional formulations comprising TPGS-1000 in the excipient base were tested. The excipient base and corresponding additive were melted at 50 °C and stirred in glass vials for 24 hours. 10 mg / g of celastrol was added, and the solution was stirred at 50 °C for about 30-60 minutes until the celastrol was fully dissolved. About 500 mg of the formulation was pipetted into size #0 gelatin capsules and allowed to solidify at room temperature before capsules were closed by hand. Capsules were placed in 20 ml glass vials with an oxygen scavenger, and the vial headspace was filled with nitrogen. The capsules were placed in accelerated (40°C / 75%R.H.) and long-term (25°C / 60%R.H.) conditions. At sampling points, the capsule caps were removed. The capsule contents were dissolved with 5 ml of methanol for about 15 minutes at 50 °C. The samples prepared with Solutol HS-15 were dissolved with ethanol instead of methanol. 1 ml of each solution was pipetted forHPLC analysis. The sample combinations and stability results on day 0, 10, and 30 are shown in Table 6 below.Attorney Docket No.: 045898-510001WOTable 6. Stability of additional lipid formulations comprising celastrol._ Formulation Tot al related subst ances, %25°C / 6( )%R.H. 40°C / 7. 5%R.H.Semi-solid blend Additive Od10 days 30 days 10 days 30 days 75%Gelucire0.15 4.87 8.15 6.86 8.45 44 / 14+24%TPGS-100075%Cremophor 1% a- 0.15 0.57 0.67 0.72 0.91 RH40+24%TPGS-1000 Tocopherol75%Solutol HS- 0.12 0.34 0.55 0.58 2.20 15+24%TPGS-100075%TPGS- NA 0.08 0.28 0.48 0.41 0.811000+25%PEG400

[0082] The additional tested formulations demonstrate a decrease in stability compared to the formulation comprising only TPGS-1000 as the excipient base.

[0083] The disintegration of celastrol in TPGS- 1000-based formulations and Gelucire 44 / 14-based formulations was also investigated. The disintegration of Gelucire 44 / 14-based formulations was much faster than the disintegration of TPGS-1000-based formulations. Accordingly, two TPGS- 1000-based formulations (LF 1 and LF 2) were further tested in the PK studies of Example 4 (see Table 17).Example 2 - Common Capsules or Tablets

[0084] In another experiment, the use of micronization technology and functional excipients (permeation enhancers or surfactants) in making oral formulations was evaluated.

[0085] Micronized celastrol, osmotic enhancer SLS, Labrasol ALF, and Labrafil M 1944CS were used in the first-round screening of common tablets.

[0086] Celastrol was pulverized using a jet mill. The milled material was collected and tested for appearance, PSD, impurities, and crystal form. The micronized celastrol was manually sieved through an 80 mesh screen. Celastrol, MCC, lactose, CMS-Na, HPC, and colloidal silicon dioxide were sequentially added to a 100 ml mixing drum and mixed for five minutes. The mixture was then manually sifted through a 40 mesh screen. The pre-blended and sifted material was then mixed in a 100 ml mixing bin for 20 minutes. The parameters of dry granulation were adjusted by ribbon properties during processing. Magnesium stearate was passed through a 60 mesh sieve, weighed, and added to the mixing drum, and mixed for 5 minutes. Tablets were then compressed to ensure proper weight and hardness.

[0087] The composition of the batches from the first process is detailed in Table 7 below.Attorney Docket No.: 045898-510001WOTable 7. Formulations of common tablets.Batch No. Tablet 1 Tablet 2 Tablet 3 Tablet 4Primary Micronized Primary Micronized Primary Micronized Formulation Primary MicronizedCelastrol +SLS Celastrol +Labrasol ALF Celastrol +Labrafil M information Celastrol1944CS Batch size / g 30 30 30 30Unit Unit Unit Unit Materials w / w% w / w% w / w% w / w% formula / mg formula / mg formula / mg formula / mgIntra- granulationCelastrol 4.0 4.0 4.0 4.0 4.00 4.00 4.00 4.00 MCC 59.0 59.0 57.67 57.67 57.6 57.6 54.9 54.9 Lactose 29.5 29.5 28.83 28.83 28.8 28.8 27.5 27.5 Sodium Starch3.0 3.0 3.0 3.0 3.00 3.0 3.00 3.0 GlycolateColloidal1.0 1.0 1.0 1.0 1.00 1.0 5.00 5.0 Silicon DioxideHPC 3.0 3.0 3.0 3.0NA SLS 2.0 2.0 NA Labrasol ALF 5.00 5.0Labrafil M NANA NA 5.00 5.0 1944CSVitamin E 0.10 0.10 0.10 0.10 Extra-granulationMagnesium0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 StearateTotal 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0

[0088] In a second process, the celastrol was pulverized using a jet mill. The milled material was collected and tested for appearance, PSD, impurities, and crystal form. The micronized celastrol was manually sieved through an 80 mesh screen. Lactose and colloidal silica were manually premixed for 5 minutes and sifted through a 40 mesh screen. Vitamin E, Labrasol, and / or Labrafil were added slowly to the premixture, then the premixture was pelletized. Last, the premixture was rubbed by hand until it was uniform. The premixed material and celastrol, MCC, CMS-Na, and a-tocopherol were added to a 200 ml mixing drum, mixed for 10 minutes, and manually sifted through a 40 mesh screen. In a second blending step, the sifted material was placed in a 200 ml mixing drum and mixed for 5 minutes. Tablets were then compressed to ensure proper weight and hardness.

[0089] The composition of the batches from the second process is detailed in Table 8 below. Table 8. Formulations of common tablets.Batch No. Tablet 5 Tablet 6Secondary Micronized celastrol, (D90< Secondary Micronized celastrol (D90< Formulation informationlOum) 10 uni)+I .abrasol ALF Batch size / g 30 30Materials Unit formula / mg w / w% Unit formula / mg w / w%Intra-granulationCelastrol 4.0 4.0 4.0 4.0 MCC 58.0 58.0 54.6 54.6Lactose 29.0 29.0 27.3 27.3Attorney Docket No.: 045898-510001WOBatch No. Tablet 5 Tablet 6Secondary Micronized celastrol, (D90< Secondary Micronized celastrol (D90< Formulation informationlOum) 10 um)+Labrasol ALF Sodium Starch Glycolate 3.0 3.0 3.0 3.0 Colloidal Silicon Dioxide 3.0 3.0 5.0 5.0 HPC 2.0 2.0 NALabrasol ALF 5.0 5.0NAVitamin E 0.1 0.1Extra-granulationMagnesium Stearate 1.0 1.0 1.0 1.0Total 100.0 100.0 100.0 100.0

[0090] The stability of tablets made using these formulations was tested in open and accelerated conditions (40°C±2°C / 75%±5%RH). The results are presented in Table 9 below. Table 9. Stability of common tablets.Stability Formulation Total Batch No. Time / Day Water content% Assay%condition information impurities% 0 0.03 98.9 N.D Celastrol Celastrol 10 0.02 98.8 N.D 30 0.08 98.5 N.D 0 3.75 99.6 N.D Primary micronizedTablet 2 10 4.33 99.2 0.14Celastrol +SLS28 5.54 99.4 0.30 40°C±2°C Primary micronized 0 3.35 101.5 0.03 / 75%±5% Tablet 4 Celastrol +Labrafil M 10 4.43 102.1 0.29 RH, Open 1944CS 28 5.28 100.0 0.340 4.31 99.8 0.07 Secondary micronizedTablet 5 10 5.06 96.4 1.90Celastrol21 6.03 95.3 3.01 Secondary micronized 0 4.59 100.1 N.D Tablet 6 Celastrol +Labrasol 10 4.39 99.9 0.09ALF21 5.21 97.2 0.12

[0091] There was not a significant difference in water content or the assay between the four batches of common tablets. However, the two batches with SLS and Labrasol ALF were more stable than the other two batches.

[0092] The dissolution profiles of different tablets were tested in 900 ml of water with USP II paddles. The rotation speed was 75 rpm for the first 60 minutes and 250 rpm for the final 30 minutes. The results of the dissolution tests are shown in Table 10 below.Table 10. Dissolution of common tablets in water.Batch No. Tablet 1 Tablet 2 Tablet 3 Tablet 4 Tablet 5 Tablet 6PrimaryPrimary Secondary Primary Primary Micronized Secondary Formulation Micronized Micronized Micronized Micronized Celastrol Micronized information Celastrol Celastrol Celastrol Celastrol +SLS +Labrafil M Celastrol+Labrasol ALF +Labrasol ALF1944CSTime / min Dis. / % RSD% Dis. / % RSD% Dis. / % RSD% Dis. / % RSD% Dis. / % RSD% Dis. / % RSD%Attorney Docket No.: 045898-510001WO5 5 3 13 6 4 5 0 NA 5 6 2 14 10 6 3 14 5 4 3 0 NA 6 5 3 16 15 8 3 14 6 4 4 0 NA 7 7 3 22 20 8 3 15 5 4 9 0 NA 7 10 4 19 30 9 2 15 6 4 1 0 NA 8 6 4 15 45 9 4 16 4 4 8 0 173 8 4 4 18 60 11 4 17 6 4 4 1 5 9 6 4 1390 12 6 18 6 4 4 1 16 10 5 4 21

[0093] All six batches of tablets failed to reach a dissolution plateau and only released 5- 20% in 90 minutes. The batch with secondary micronized celastrol and Labrasol ALF (Tablet 6) was chosen for the pK study of Example 4 based on its stability data.Example 3. - Amorphous Solid Dispersions (ASDs)

[0094] In a further experiment, amorphous solid dispersions of celastrol in different polymers were evaluated. In this experiment, first, methanol, ethanol, acetone, tetrahydrofuran, and di chloromethane were independently screened as solvents for celastrol.10 mg of celastrol was added to 1 ml of solvent and briefly shaken. Celastrol was added in 10 mg increments with shaking between each addition until an insoluble substance was visible. The solution was shaken vigorously for 30-60 seconds every 5 minutes to confirm the visual solubility. The celastrol had good solubility > 30 mg / ml in methanol, acetone, tetrahydrofuran, and di chloromethane. Methanol and acetone were selected for subsequent ASD experiments in view of their relatively higher residual limits and faster drying times.

[0095] Methanol, ethanol, acetone, THF, and DCM were then also independently screened as solvents for the polymers. 50 mg of polymer was added to 1 ml of solvent and shaken. Polymer was added in 50 mg increments with shaking between each addition until an insoluble substance was visible. The solution was shaken vigorously for 30-60 seconds every 5 minutes to confirm the visual solubility. Methanol and acetone were selected for subsequent ASD experiments in view of their relatively higher residual limits and faster drying times. Soluplus, Kolidon VA64, HPMCAS-LG, PVP-K30, HPMCP and EUDRAGIT LI 00 were selected as polymers for subsequent ASD experiments.

[0096] The spray dry solutions were prepared with a solid content of 6% (w / v). First, the celastrol was dissolved in methanol, then polymer was added and stirred until completely dissolved. The spray dryer was pre-heated to an outlet temperature of 50-60 °C. The feeding rate of blank solvent was adjusted until the inlet air temperature was 80-100 °C. The volume flow was 35 m3 / h, the gas velocity of the nozzle was 473 L / h, the rotor height was 40 mm, andAttorney Docket No.: 045898-510001WOthe atomization pressure was 0.41 bar. The solution containing the celastrol was spray dried to prepare an amorphous solid dispersion. Blank solvent was then sprayed for 5-10 minutes. The machine was stopped when the inlet air pressure was below 60 °C and the outlet air temperature was below 50 °C. The ASD was collected from the cyclone and placed as a wet cake into a vacuum drying oven with a drying temperature of 40 °C. The composition of the spray dry solutions used to prepare the ASDs is shown in Table 11 below.Table 11. Composition of spray dry solutions used to prepare ASDs.Batch No. CelastrolCelastrol: Polymer(w / w) Polymer / g Methanol / ml, Acetone / mL / gASD 1 Celastrol: Soluplus =l:3 0.3019 0.9015 20 N / A Celastrol: PVP-VA640.3006 0.9003 20 N / AASD 2 =1:3Celastrol: HPMCAS-LG0.3007 0.9006 20 N / AASD 3 =1:3ASD 4 Celastrol: PVP-K30 =1:3 0.3018 0.9003 20 N / A Celastrol: EUDRAGIT0.3015 0.9009 20 N / AASD 5 L100 =l:3ASD 6 Celastrol: HPMCP =1:3 0.3008 0.9032 N / A 20

[0097] The formulations containing HPMCAS-LG, PVP-K30, PVP-VA64 and HPMCP had better solubility than other ASDs in FaSSIF, but impurities in the HPMCP formulation were relatively high. The kinetic solubility of different ASDs dissolved in FaSSIF for two hours is shown in Table 12 below.Table 12. Kinetic solubility of ASD batches in 2 hours in FaSSIF.FaSSIF (mg / ml)Batch No. Sample Name0.5h Ih 2h PH Celastrol Celastrol 0.0322 0.0425 0.0314 6.34 ASD 1 Celastrol : Soluplus( 1:3) 0.0683 0.0684 0.0727 6.13 ASD 2 Celastrol: PVP-VA64(1:3) 0.1325 0.3345 0.4907 6.44 ASD 3 Celastrol: HPMCAS-LG(1:3) 0.2193 0.5176 0.6991 6.12 ASD 4 Celastrol: PVP-K30(l:3) 0.2824 0.4726 0.6411 6.38 ASD 5 Celastrol : Eudragit-L 100(1:3) 0.1979 0.3540 0.3774 6.11ASD 6 Celastrol: HPMCP(1:3) 0.2443 0.3975 0.4982 6.01

[0098] The formulations were unstable in stimulated gastric fluid, with degradants in the range of 50-80%. HPMCAS-LG, PVP-K30 and PVP-VA64 had certain advantages in maintaining the supersaturation of celastrol in FaSSIF. The summary of impurities of different ASDs are shown in Table 13 below.Table 13. Summary of total impurities of ASDs.Batch No. Formulation information Total Impurity%(FaSSIF) Total Impurity%(SGF) Celastrol Celastrol 0.13 75.851ASD 1 Celastrol : Soluplus( 1:3) 0.20 72.293ASD 2 Celastrol: PVP-VA64(1:3) 0.25 73.673ASD 3 Celastrol: HPMCAS-LG(1:3) 0.25 62.396ASD 4 Celastrol: PVP-K30(l:3) 0.27 74.103Attorney Docket No.: 045898-510001WOASD 5 Celastrol : Eudragit-L 100( 1 : 3 ) 4.13 77.192ASD 6 Celastrol: HPMCP(1:3) 0.91 55.118

[0099] Additional batches of ASDs were prepared using a similar process as the process described above. The composition of the second batch of samples is shown in Table 14 below. Table 14. Composition of spray dry solutions used to prepare ASDs.Batch No. Celastrol: Polymer(w / w) Celastrol / g Polymer / g Methanol / mL ASD 7 Celastrol: PVP-VA64 =1:3 1.5018 4.5076 100Celastrol: HPMCAS-LGASD 8 1.5029 4.5008 100=1:3ASD 9 Celastrol: PVP-K30 =1:3 1.5055 4.5014 100

[0100] Under accelerated conditions (40°C±2°C, 75%±5%RH), the ASD 7 showed fewer impurities than the other ASDs. An increase in moisture content over time was prevented by sealing the samples with a desiccant in two-layer LDPE bags or aluminum foil bags. The results of the preliminary stability study of different ASDs are shown in Table 15 below.Table 15. Stability of ASDs.Stability Formulation Time / Batch No. Water content% Assay% Total impurities% condition information Day0 0.03 98.9 N.D Celastrol Celastrol 10 0.02 98.8 N.D 28 0.08 98.5 N.D 0 2.87 99.5 0.05 Celastrol: PVP- ASD 7 10 3.24 98.2 0.05VA64(1:3)40°C±2°C> 28 4.03 98.2 0.11 75%±5%RH Celastrol: 0 1.39 102.2 0.04ASD 8 HPMCAS- 10 1.52 100.1 0.50LG(1:3) 28 1.95 99.7 1.310 4.19 99.0 0.05 Celastrol: PVP- ASD 9 10 4.87 97.5 0.23K30(l:3)28 5.90 97.0 0.36

[0101] The kinetic solubility of the second series of batches of ASDs was monitored for 28 days. The results are shown in Table 16 below.Attorney Docket No.: 045898-510001WOTable 16. Kinetic solubility of ASDs.Formulation 0 D 10 D 28D Batch No.information 0.5h Ih 2h 0.5h Ih 2h 0.5h Ih 2h Celastrol Celastrol 0.0035 0.0067 0.0077 0.0128 0.0125 0.0165 0.0033 0.0054 0.0071Celastrol:ASD 7 PVP- 0.4863 0.8390 0.9695 0.2507 0.6337 0.8605 0.2063 0.6182 0.9647VA64=1:3Celastrol:ASD 8 HPMCAS- 0.3175 0.8762 1.0307 0.6347 0.8038 0.8679 0.4045 0.9285 1.1265LG=1:3Celastrol:ASD 9 0.6306 0.8771 1.0210 0.4043 0.4820 0.5810 0.2224 0.8180 1.0718PVP-K30=l:3

[0102] ASD 7 and ASD 9 were selected for further studies (Example 4) based on their 28-day stability data.Example 4 - PK Study

[0103] Two PK experiments were conducted. The samples for the first experiment were dosed to beagle dogs as sample suspensions. The second experiment was conducted to assess the differences between two ASD formulations.

[0104] The dose level of each sample was 2 mpk, and each group contained three male dogs. The samples were administered under fasted conditions (no food intake overnight before and 4 h after dosing). A summary of the samples tested across the two experiments and the dosing regimen is in Table 17 below.Table 17. Summary of formulations used in PK study.Form of administrationFormulation Name Group No.Batch No. 1stPK 2ndPKcelastrol suspension inG1 Celastrol Suspension NA0.01%v / v tween 80celastrol: PVP- G2 ASD 7 Suspension SuspensionVA64=1:3celastrol: PVP-K30=l:3 G3 ASD 9 Suspension NACommon tablets / capsules(Micronized Celastrol G4 Tablet 6 Suspension NA+Labrasol ALF)LF 1 NA NALipid formulation Semi-solid inG5(Celastrol in TPGS-1000) LF 2 gelatin NAcapsule

[0105] Each suspension was administered in a dose volume of 5 mL / kg and concentration of 0.4 mg / mL and delivered via oral gavage. For group G5 in the 1stPK experiment, two or three gelatin capsules were dosed via PO.Attorney Docket No.: 045898-510001WO

[0106] At 0.083h, 0.25h, 0.5h, Ih, 2h, 4h, 8h and 24h post-dose, -500 of whole blood was collected via the jugular vein, placed in tubes with EDTA-K2 as an anti-coagulant, and centrifuged to obtain plasma in 30 minutes. Whole blood samples were kept on wet ice until centrifugation. A total of 24*5 plasma samples were collected and kept on dry ice or stored in the freezer until the time of bioanalysis.

[0107] The second PK experiment was a cross-PK trial with ASD 7, using the three dogs that were dosed with ASD 9 in the 1stPK trial, to differentiate the variability in animals between the two formulations. The results of the 1stand 2ndPK trial are shown in Table 18 below.Table 18. Summary of the first and second PK experiments.In-vivo performance PK TrialFormulation Name Group Batch No.Stage category Ave. Cmax CV / % Ave. AUC CV / %2ndParallelcelastrol G1 Celastrol 94.8±35.8 37.36 422±72.6 17.20 round test2ndParallelCelastrol : PVP- VA64= 1 : 3(ASD 7) G2 ASD 7 106±22.1 20.85 594±209 35.19 round test3rdCelastrol : PVP- VA64= 1 : 3(ASD 7) G3 ASD 7 222±63.7 28.69 1335±179 13.44 round Cross2ndtestCelastrol: PVP-K30=l:3(ASD 9) G3 ASD 9 114±10.4 9.12 580±25.0 4.31 round2ndParallel Common tablets / capsulesG4 Tablet 6 64.9±10.7 16.49 269±79.2 29.44 round test (Micronized Celastrol +Labrasol ALF)2ndParallel Lipid formulation 316±157 49.68G5 LF 2 127±67.6 53.23round test (Celastrol in TPGS-1000)Cage side observationIn Group 1, animal No.102 had less activity 8min post dose. Symptoms disappeared 4h post dose;In Group 1, animal No.103 vomited 4h and 8h post dose. Symptoms disappeared 23h49min post dose; In Group 3, 2ndround, animal No.301 vomited 8h post dose. Symptoms disappeared 24h post dose;In Group 3, 2ndround, animal No.302 vomited and had soft stools and less activity 8h post dose. Symptoms disappeared 24h post dose;In Group 4, animal No.402 vomited and had mucinoid stools and less activity 8h post dose. Symptoms disappeared 24h post dose;In Group 5, animal No.502 vomited and had mucinoid stools 8h post dose. Symptoms disappeared 24h postdose.

[0108] Based on the 2ndround result, ASD 7 (Celastrol: PVP-VA64=1:3) showed the best Cmax and exposure (AUC) as compared with the other formulations, including the control group. The exposure of ASD 7 was 3.2 and 2.3 times that of the control group and ASD 9, respectively. Additionally, the inter-animal variability (CV%) of ASD 7 decreased significantly from 35% in the 1stround of PK trials to 13% in the 2ndround. In view of its in-vivo bioavailability, low variability, and stability, ASD 7 was selected for tablet development.

[0109] Additional stability studies on ASD 7 (Celastrol: PVP-VA64=1:3) and ASD 9 (Celastrol: PVP-K30=l:3) were performed at 2-8°C, 25°C / 60%RH, and 40°C / 75%RH over 30Attorney Docket No.: 045898-510001WOdays. ASD 7 showed superior stability (with total impurities consistently no higher than 0.05%, over 30 days even under accelerated conditions) while ASD 9 had an increasing trend in total impurities over time.Example 5 - Celastrol ASD Tablets

[0110] Based on the PK trials and preliminary stability studies, the polymer Kollidon VA64 was chosen for the next round of ASD formulations. Two batches were prepared to study excipient compatibility and formulation process development, respectively, as shown in Table 19 below.Table 19. Composition of spray dry solutions used to prepare ASDs.Solution Formulation CelastrolBatch No. Polymer / g Methanol / mL solidcomposition / g contentl'm / v) Celastrol: PVA- ASD 10 10.1411 30.0080 667 6.0% VA64=l:3(m / m)Celastrol: PVA- ASD 11 40.20 120.0122 2667 6.0%VA64=l:3(m / m)[OHl] Several batches of tablets were made to evaluate the effects of different fillers, binders, and disintegrants, and their amounts. To make the tablets, the prescribed amounts of celastrol ASD and intragranular excipients were sequentially added to a blending bin, then mixed for 10 minutes at the speed of 10 rpm. Each mixture was manually sifted through a 40-mesh sieve. The pre-blended and sifted material was placed in a suitable blending bin and mixed for 20 minutes at 10 rpm. Dry granulation was conducted based on the set parameters and monitor ribbon properties during processing. Magnesium stearate was passed through a 6-mesh screen, added to the mixing drum, and mixed for 5 minutes at 10 rpm. The compression parameters were adjusted to achieve suitable weight and hardness for pressing tablets. Tablets then gained 4% coating weight as a target, with 2% to 5% coating weight being an acceptable range. The ingredients of each formulation are detailed in Table 20.Table 20. Composition of ASD tablet formulationsFormulatioFl F2 F6 F3 F7 F4 F5 F8 n No.Strength 2mgMCC :MCC : MCC : Mannitol=4: 1 MCC, noFormulatio MCC : Cellactose Ce2 SiO2, llactose , %CMS- n MCC : MCC : 80=4:1, 80=4:1,Mannitol=4:l MCC Na, no HPCinformatio Mannitol=2: 1 Mannitol=4: 1 Pre-stability n no HPC blending time Pressing Pre-stability and coating study study study weight gainstudyAttorney Docket No.: 045898-510001WOBatch30 30 30 30 200 500 150 150 size / gUnit Unit Unit Unit Unit Unit Unit Unit w / w w / w w / w w / w w / w w / w w / w w / w Ingredients formula formula formula formula formula formula formula formula % % % % % % % % / mg / mg / mg / mg / mg / mg / mg / mg Intra-granulationCelastrol8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 ASDMicrocrystalline54. 65. 69. 67. 67. cellulose, 54.7 65.6 68 68 82 82 69.6 84 84 67.2 67.27 6 6 2 2 MCC UF702Mannitol, 1 27. 16. 17.27.3 16.4 17 17 NA NA 17.4 NA NA NA NA NA NA 00SD 3 4 4Cellactose 16. 16.NA NA NA NA NA NA NA NA NA NA NA NA 16.8 16.8 80 8 8 SodiumStarch4 4 4 4 4 4 4 4 2 2 5 5 5 5 5 5 Glycolate,CMS-NaHydroxypropylCellulose, 3 3 3 3 NA NA 3 3 NA NA 2 2 2 2 2 2 HPC EXFPharmaColloidalSiliconDioxide,2 2 2 2 2 2 2 2 2 2 NA NA NA NA NA NA Aerosil200PharmaExtra-granulationMagnesium Stearate,LIGAME1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 D,MF-2-V- MBFilm- coated Opadry Opadry premix premix A or premix C (gastric NA NA NA NA NA NA B 2, 3, 5% soluble) 3% coating coating Opadry weight gain weight gain YellowOverlubricationwhen tablet TargetRemark NA NA NA NA NA NA compression formulationwith forcedfeeder

[0112] Tablet formulations Fl, F2, F3, F4, and F5 were used to study filler types and amounts. All the batches of different fillers met the requirements of blend uniformity and dissolution. Fl and F2 were sticky on the rollers. This could be improved by reducing the amount of mannitol. However, as cellactose 80 resulted in fewer impurities than mannitol in an ASD compatibility study, mannitol was replaced with cellactose 80 in certain tablet formulations. Additionally, colloidal silicon dioxide resulted in over 14% impurities after 4 weeks at 25°C / 90%R.H in the ASD excipient computability study. Removing colloidal silicon dioxide from the formulation led to a trend of over-lubrication during the pressing process.Attorney Docket No.: 045898-510001WOCellactose 80 also served as a brittle excipient to avoid over-lubrication. F5 with MCC: Cellactose 804: 1 was chosen for further development.

[0113] F2, F6, and F5 were used to study binder amounts. All of the batches of different binder amounts met the requirements of dissolution. To ensure the formability of the ribbon and compressibility of the downstream tableting, F5 with 2% HPC was chosen for further development.

[0114] F6, F7, and F5 were used to study disintegrants. All of the batches of different disintegrants met the requirements of dissolution. The disintegration time was extended when the disintegrant amount was decreased from 5% to 2%. To meet the requirement of rapid release, the amount of disintegrant was set to 5%.

[0115] F5 was film-coated with one of two Opadry Yellow premixes at 3% weight gain to produce F5-1 and F5-2. F8 was film-coated with a third Opadry Yellow premix at 2%, 3%, and 5% weight gain. The three coating powder mixtures are detailed in Table 21 below.Table 21. Composition of tablet coatings.ASD Formulation F5-1 F5-2 F-8 Opadry premix Opadry premix A Opadry premix B Opadry premix C Ingredient ListPolyvinyl Alcohol-part.Hydrolyzed(PVA)Gmdcc, Gmcc type 1 ,Polyvinyl Alcohol-part.Mono / Di-glycerides,Hydrolyzed(PVA) Hydroxypropyl Glycerol methylcellulose(HPMC) Titanium dioxideMacrogol(PEG) polyvinyl Macrogol(PEG) alcohol graft copolymer TalcTitanium dioxide Titanium dioxide Ferric oxide yellowFerric oxide yellowTalc Ferrosoferric oxide / Blackiron oxideFerric oxide yellowFerrosoferric oxide / Blackiron oxide

[0116] Coated tablets that were stored in an HDPE bottle and capped with a polypropylene screw-on cap with 2 grams of desiccant had no significant difference in water content, dissolution, and impurities as compared with the initial sample after storage for one month under accelerated conditions, except F5-1 showed an increasing trend in total impurities. The coating powder used in F5-2 was taken forward for further studies because it does not contain plasticizers or surfactants. Without wishing to be bound by theory, the lipid formulation experiments suggested that certain plasticizers or surfactants could lead to celastrol degradation.

[0117] F6 and F7 were used to study dissolution in different media with different rotation speeds. Without the addition of 0.5% surfactant SDS in a dissolution medium with a pH of 6.8,Attorney Docket No.: 045898-510001WOthe tablets were not fully released. The results of the dissolution experiment are detailed in Table 22 below.Table 22. Dissolution of ASD tablets.Batch No. F6 F7Strength 2 mg 2mgBatch size / g 30 200 Formulation MCC: Mannitol=4:l, MCC: Mannitol=4:l, information 4%CMS-Na, no HPC 2%CMS-Na, no HPC Ingredients Unit formula / mg w / w% Unit formula / mg w / w% Celastrol8.0 8.0 8.0 8.0 ASD MCC 68.0 68.0 69.6 69.6 Mannitol 17.0 17.0 17.4 17.4 CMS-Na 4.0 4.0 2.0 2.0 HPC NA NA NA NASiO22.0 2.0 2.0 2.0 Mg-St 1.0 1.0 1.0 1.0 Total 100 100 100 100pH6.8+0%SDS, pH6.8+0.5%SDS, pH6.8+0.5%SDS, pH6.8+0.5%SDS, pH6.8+0.5%SDS, Media900ml, 75rpm 900ml, 75rpm 900ml, 50rpm 900ml, 50rpm 900ml, 75rpm Hardness / N 38-48 38-48 38-48 29-59 29-59 Time / min Dis. / % RSD% Dis. / % RSD% Dis. / % RSD% Dis. / % RSD% Dis. / % RSD% 5 0 0 85 1 60 0 45 30 60 46 10 4 6 94 1 80 8 73 7 85 11 15 6 8 95 0 86 6 82 2 92 2 20 9 4 95 1 89 5 87 1 94 1 30 12 1 96 0 91 5 90 0 95 2 45 16 6 95 1 93 4 92 1 96 3 60 20 3 96 1 95 2 94 1 96 290 27 5 97 0 97 1 95 2 96 3

[0118] Because celastrol is unstable under light, all processes were operated avoiding light. Spray dry solutions were formulated at 8% solution solid content using methanol as the solvent. The prescribed amount of methanol was added to a mixing tank and stirred to form a vortex. The prescribed amount of celastrol was added and dissolved before the prescribed amount of Kollidon VA64 was added and stirred until dissolved. The spray dryer was preheated with an inlet air temperature set to 80-100 °C, an outlet air temperature set to 45-65 °C, a feeding rate of 3-7 kg / h, and a nozzle atomizing air flow of 5-15 kg / h. When the inlet and outlet temperatures were stable, the drug-containing solution was spray dried to prepare the amorphous solid dispersion. At the end of spray drying, the blank solvent was sprayed for 5-10 minutes before the machine was cooled and the wet ASD products were collected. The wet ASD cake was placed into a vacuum drying oven at 40±2 °C and <-0.8 bar and turned over every 2-4 hours until the methanol residue was below 3000 ppm. The prescribed amount of ASD, MCC, Cellatose 80, HPC, and CMS-Na were sequentially placed in a suitable blending bin and mixed at 10 rpm for 10 minutes then manually sifted through a 40 mesh screen. The pre-blend was placed in an appropriate blending bin and mixed at 10 rpm for 20 minutes. ForAttorney Docket No.: 045898-510001WOroller compaction, the hydraulic pressure was set to 40-60 bar, the roller gap was set at 1.0-3.0 mm, the roller speed was fixed at 3.0-7.0 rpm, the coarse screen was 2.00 mm, the fine screen was 1.00 mm, and the granulation speed was set at 100 rpm. After roller compaction, the remaining particles were weighed. Extragrannular magnesium stearate was passed through a 60 mesh screen and planed into a suitable blending bin for blending at 10 rpm for 5 minutes. Tableting process parameters were adjusted to ensure the appropriate weight and hardness of the tablets. The weight of the tablets was controlled at ±7.5% during compression.

[0119] Coating solution with 1.5 times the prescribed amount of film coating premix was prepared with a 10-20% solid content using water as a dispersant. The film coating premix was slowly added while stirring, and stirring was maintained for at least 45 minutes. The coating pan was pre-heated for 5 minutes before the tablets were coated with an air inlet temperature of 50-70 °C, an air flow of 50-80 m3 / h, a pan speed of 10-20 rpm, a feeding speed of 5g / min, and an atomizing pressure and fan pressure of 1.0-2.0 bar. The tablet bed temperature was maintained at 40-50 °C. Once the theoretical spraying liquid volume was fully sprayed, samples were weighed, and spraying was continued if necessary until the target coating rate of 4% (with a range of 2-5%) was reached.

[0120] After lab-scale and formulation development and process optimization, the final formulation and process parameters are shown in Table 23 below.Table 23. Composition of optimized ASD tablet formulation.Ingredients Theoretical weight (mg / unit) w / w(%)Spray DryingCelastrol *!2.0 2.0 Copovidone 6.0 6.0 Methanol*279.1 N / A Core TabletMicrocrystallline cellulose, UF702 67.2 67.2Cellatose 80 16.8 16.8 Hydroxypropyl Cellulose, EXF Pharma 2.0 2.0 Sodium Starch Glycolate, CMS-Na 5.0 5.0 Magnesium stearate 1.0 1.0 Total 100.0 100.0CoatingFilm-coated premix (gastric soluble)-Opadry®*34.0 Weight gain 4% Purified water*422.7 N / ATotal 104.0 N / A*' The actual feeding amount of celastrol needs to be converted according to the assay and water content. Actual feeding amount =The theoretical amount / Assay*(l-water content)*2Methanol is the solvent for spray drying and will be removed from the process. The density of methanol is 0.791mg / mL. *3The coating powder will be prepared into a coating solution with a solid content of 15% (m / m).*4The purified water is the solvent for the coating solution and will be removed from the coating process.Attorney Docket No.: 045898-510001WOEnumerated EmbodimentsEmbodiment 1. A liquid formulation comprising:(i) celastrol;(ii) a polymer; and(iii) a solvent.Embodiment 2. The liquid formulation of embodiment 1, wherein the solvent is an alcohol.Embodiment s. The liquid formulation of embodiment 1, wherein the alcohol is methanol.Embodiment 4. The liquid formulation of embodiment 1, wherein the solvent is acetone. Embodiment s. The liquid formulation of any one of embodiments 1-5, wherein the concentration of celastrol in the liquid formulation is from about 10 mg / mL to about 20 mg / mL.Embodiment 6. The liquid formulation of any one of embodiments 1-5, wherein the concentration of celastrol in the liquid formulation is about 15 mg / mL.Embodiment 7. The liquid formulation of any one of embodiments 1-7, wherein the concentration of the polymer in the liquid formulation is from about 30 mg / mL to about 70 mg / mL.Embodiment s. The liquid formulation of any one of embodiments 1-7, wherein the concentration of the polymer in the liquid formulation is from about 40 mg / mL to about 50 mg / mL.Embodiment 9. The liquid formulation of any one of embodiments 1-7, wherein the concentration of the polymer in the liquid formulation is about 45 mg / mL.Embodiment 10. The liquid formulation of any one of embodiments 1-7, wherein the concentration of the polymer in the liquid formulation is from about 50 mg / mL to about 70 mg / mL.Embodiment 11. The liquid formulation of any one of embodiments 1-7, wherein the concentration of the polymer in the liquid formulation is from about 55 mg / mL to about 65 mg / mL.Attorney Docket No.: 045898-510001WOEmbodiment 12. The liquid formulation of any one of embodiments 1-7, wherein the concentration of the polymer in the liquid formulation is about 60 mg / mL.Embodiment 13. The liquid formulation of any one of embodiments 1-13, wherein the liquid formulation is for preparing an amorphous solid dispersion.Embodiment 14. The liquid formulation of any one of embodiments 1-14, wherein the liquid formulation is for preparing an amorphous solid dispersion by spray drying the liquid formulation.Embodiment 15. A method for preparing an amorphous solid dispersion comprising spray drying the liquid formulation of any one of embodiments 1-15.Embodiment 16. An amorphous solid dispersion comprising:(i) celastrol; and(ii) a polymer.Embodiment 17. The amorphous solid dispersion of embodiment 17, wherein the amorphous solid dispersion is made by spray drying liquid formulation of any one of embodiments 1-15.Embodiment 18. The liquid formulation or amorphous solid dispersion of any one of embodiments 1-17, comprising the celastrol and the polymer at a wt / wt ratio of from about 1:5 to about 1:1.Embodiment 19. The liquid formulation or amorphous solid dispersion of any one of embodiments 1-18, comprising the celastrol and the polymer at a wt / wt ratio of about 1 :3. Embodiment 20. The liquid formulation or amorphous solid dispersion of any one of embodiments 1-20, wherein the polymer is hydroxypropyl methylcellulose acetate succinate (HPMCAS).Embodiment 21. The liquid formulation or amorphous solid dispersion of any one of embodiments 1-20, wherein the polymer is a water-soluble polymer.Embodiment 22. The liquid formulation or amorphous solid dispersion of embodiment 22, wherein the water-soluble polymer is hydroxypropyl methylcellulose phthalate (HPMCP).Embodiment 23. The liquid formulation or amorphous solid dispersion of embodiment 22, wherein the water-soluble polymer comprises l-vinyl-2-pyrrolidone monomers.Attorney Docket No.: 045898-510001WOEmbodiment 24. The liquid formulation or amorphous solid dispersion of embodiment 22, wherein the water-soluble polymer comprises l-vinyl-2-pyrrolidone monomers and vinyl acetate monomers.Embodiment 25. The liquid formulation or amorphous solid dispersion of embodiment 22, wherein the water-soluble polymer is copovidone.Embodiment 26. The liquid formulation or amorphous solid dispersion of embodiment 22, wherein the water-soluble polymer is povidone.Embodiment 27. The liquid formulation or amorphous solid dispersion of embodiment 22, wherein the water-soluble polymer comprises caprolactam monomers, polyvinyl acetate monomers, and polyethylene glycol monomers.Embodiment 28. The liquid formulation or amorphous solid dispersion of embodiment 28, wherein the water-soluble polymer is a polyvinyl caprolactam-polyvinyl acetatepolyethylene glycol graft copolymer.Embodiment 29. The liquid formulation or amorphous solid dispersion of embodiment 28, wherein the water-soluble polymer comprises polyethylene glycol 6000 (PEG 6000), vinylcaprolactam and vinyl acetate at a wt. / wt. / wt. ratio of about 13:57:30.Embodiment 30. The liquid formulation or amorphous solid dispersion of embodiment 22, wherein the water-soluble polymer comprises acrylic acid monomers.Embodiment 31. The liquid formulation or amorphous solid dispersion of embodiment 31, wherein the water-soluble polymer is a polymethacrylate.Embodiment 32. The liquid formulation or amorphous solid dispersion of embodiment 31, wherein the water-soluble polymer is a co-polymer comprising methacrylic acid monomers and methyl methacrylate monomers at a monomer ratio of about 1 :2.Embodiment 33. The liquid formulation or amorphous solid dispersion of embodiment 31, wherein the water-soluble polymer is an anionic co-polymer comprising methacrylic acid monomers and methyl methacrylate monomers at a monomer ratio of about 1:1. Embodiment 34. The liquid formulation or amorphous solid dispersion of embodiment 31, wherein the water-soluble polymer is a poly(methacrylic acid-co-methyl methacrylate). Embodiment 35. A pharmaceutical composition comprising the amorphous solid dispersion of any one of embodiments 17-35.Attorney Docket No.: 045898-510001WOEmbodiment 36. A pharmaceutical composition comprising celastrol and a polymer. Embodiment 37. The pharmaceutical composition of embodiment 37, wherein celastrol is present in an amount of from about 0.5 wt.% to about 5 wt.% of the total components of the composition.Embodiment 38. The pharmaceutical composition of embodiment 37, wherein celastrol is present in an amount of about 4 wt.% of the total components of the composition.Embodiment 39. The pharmaceutical composition of embodiment 37, wherein celastrol is present in an amount of about 2 wt.% of the total components of the composition.Embodiment 40. The pharmaceutical composition of any one of embodiments 37-40, wherein the polymer is hydroxypropyl methylcellulose acetate succinate (HPMCAS). Embodiment 41. The pharmaceutical composition of any one of embodiments 37-40, wherein the polymer is a water-soluble polymer.Embodiment 42. The pharmaceutical composition of embodiment 42, wherein the water- soluble polymer is hydroxypropyl methylcellulose phthalate (HPMCP).Embodiment 43. The pharmaceutical composition of embodiment 42, wherein the water- soluble polymer comprises l-vinyl-2-pyrrolidone monomers.Embodiment 44. The pharmaceutical composition of embodiment 42, wherein the water- soluble polymer comprises l-vinyl-2-pyrrolidone monomers and vinyl acetate monomers. Embodiment 45. The pharmaceutical composition of embodiment 42, wherein the water- soluble polymer is copovidone.Embodiment 46. The pharmaceutical composition of embodiment 42, wherein the water- soluble polymer is povidone.Embodiment 47. The pharmaceutical composition of embodiment 42, wherein the water- soluble polymer comprises caprolactam monomers, polyvinyl acetate monomers, and polyethylene glycol monomers.Embodiment 48. The pharmaceutical composition of embodiment 48, wherein the water- soluble polymer is a polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer.Attorney Docket No.: 045898-510001WOEmbodiment 49. The pharmaceutical composition of embodiment 49, wherein the water- soluble polymer comprises polyethylene glycol 6000 (PEG 6000), vinylcaprolactam and vinyl acetate at a wt / wt / wt. ratio of about 13:57:30.Embodiment 50. The pharmaceutical composition of embodiment 42, wherein the water- soluble polymer comprises acrylic acid monomers.Embodiment 51. The pharmaceutical composition of embodiment 51, wherein the water- soluble polymer is a polymethacrylate.Embodiment 52. The pharmaceutical composition of embodiment 51, wherein the water- soluble polymer is a co-polymer comprising methacrylic acid monomers and methyl methacrylate monomers at a monomer ratio of about 1 :2.Embodiment 53. The pharmaceutical composition of embodiment 51 , wherein the water- soluble polymer is an anionic co-polymer comprising methacrylic acid monomers and methyl methacrylate monomers at a monomer ratio of about 1:1.Embodiment 54. The pharmaceutical composition of embodiment 51, wherein the water- soluble polymer is a poly(methacrylic acid-co-methyl methacrylate).Embodiment 55. The pharmaceutical composition of any one of embodiments 30-55, comprising the polymer in an amount of from about 2 wt.% to about 10 wt.% of the total components of the composition.Embodiment 56. The pharmaceutical composition of any one of embodiments 30-55, comprising the polymer in an amount of about 6 wt.% of the total components of the composition.Embodiment 57. The pharmaceutical composition of any one of embodiments 30-56, further comprising a filler.Embodiment 58. The pharmaceutical composition of embodiment 58, wherein the pharmaceutical composition comprises the filler in an amount of from about 75 wt.% to about 85 wt.% of the total components of the composition.Embodiment 59. The pharmaceutical composition of embodiment 58, wherein the pharmaceutical composition comprises the filler in an amount of from about 80 wt.% to about 90 wt.% of the total components of the composition.Attorney Docket No.: 045898-510001WOEmbodiment 60. The pharmaceutical composition of embodiment 58, wherein the pharmaceutical composition comprises the filler in an amount of about 84 wt.% of the total components of the composition.Embodiment 61. The pharmaceutical composition of any one of embodiments 58-61, wherein the filler is selected from one or more of microcrystalline cellulose (MCC), a mixture of alpha lactose monohydrate and powdered cellulose, and mannitol.Embodiment 62. The pharmaceutical composition of any one of embodiments 58-61, wherein the filler comprises microcrystalline cellulose (MCC).Embodiment 63. The pharmaceutical composition of any one of embodiments 58-61, wherein the pharmaceutical composition comprises microcrystalline cellulose (MCC) in an amount of from about 60 wt.% to about 75% of the total components of the composition. Embodiment 64. The pharmaceutical composition of any one of embodiments 58-61, wherein the pharmaceutical composition comprises microcrystalline cellulose (MCC) in an amount of about 67 wt.% of the total components of the composition.Embodiment 65. The pharmaceutical composition of any one of embodiments 58-65, wherein the filler comprises a mixture of alpha lactose monohydrate and powdered cellulose.Embodiment 66. The pharmaceutical composition of any one of embodiments 58-65, wherein the filler comprises a mixture of alpha lactose monohydrate and powdered cellulose at a ratio of about 3:1.Embodiment 67. The pharmaceutical composition of any one of embodiments 58-67, wherein the pharmaceutical composition comprises the mixture of alpha lactose monohydrate and powdered cellulose in an amount of from about 10 wt.% to about 25 wt.% of the total components of the composition.Embodiment 68. The pharmaceutical composition of any one of embodiments 58-67, wherein the pharmaceutical composition comprises the mixture of alpha lactose monohydrate and powdered cellulose in an amount of about 17 wt.% of the total components of the composition.Embodiment 69. The pharmaceutical composition of any one of embodiments 58-61, wherein the filler comprises microcrystalline cellulose (MCC) and a mixture of alpha lactose monohydrate and powdered cellulose.Attorney Docket No.: 045898-510001WOEmbodiment 70. The pharmaceutical composition of any one of embodiments 35-69, further comprising a binder.Embodiment 71. The pharmaceutical composition of embodiment 71, wherein the binder is hydroxypropyl cellulose (HPC).Embodiment 72. The pharmaceutical composition of embodiment 71 or 72, wherein the pharmaceutical composition comprises the binder in an amount of from about 0.5 wt.% to about 5% of the total components of the composition.Embodiment 73. The pharmaceutical composition of embodiment 71 or 72, wherein the pharmaceutical composition comprises the binder in an amount of about 2 wt.% of the total components of the composition.Embodiment 74. The pharmaceutical composition of any one of embodiments 35-74, further comprising a disintegrant.Embodiment 75. The pharmaceutical composition of embodiment 75, wherein the disintegrant comprises one or more of sodium starch glycolate (SSG), sodium carboxymethyl starch (CMS-Na), or polyvinylpolypyrrolidone (crospovidone).Embodiment 76. The pharmaceutical composition of embodiment 75, wherein the disintegrant is polyvinylpolypyrrolidone (crospovidone).Embodiment 77. The pharmaceutical composition of embodiment 75, wherein the disintegrant is sodium starch glycolate (SSG).Embodiment 78. The pharmaceutical composition of embodiment 75, wherein the disintegrant is sodium carboxymethyl starch (CMS-Na).Embodiment 79. The pharmaceutical composition of any one of embodiments 75-79, wherein the pharmaceutical composition comprises the disintegrant in an amount of from about 0.5 wt.% to about 10% of the total components of the composition.Embodiment 80. The pharmaceutical composition of any one of embodiments 75-79, wherein the pharmaceutical composition comprises the disintegrant in an amount of from about 2 wt.% to about 8% of the total components of the composition.Embodiment 81. The pharmaceutical composition of any one of embodiments 75-79, wherein the pharmaceutical composition comprises the disintegrant in an amount of about 5 wt.% of the total components of the composition.Attorney Docket No.: 045898-510001WOEmbodiment 82. The pharmaceutical composition of any one of embodiments 35-82, further comprising a lubricant.Embodiment 83. The pharmaceutical composition of embodiment 83, wherein the lubricant is sodium stearyl fumarate.Embodiment 84. The pharmaceutical composition of embodiment 83, wherein the lubricant is magnesium stearate.Embodiment 85. The pharmaceutical composition of any one of embodiments 83-85, wherein the pharmaceutical composition comprises the lubricant in an amount of from about 0.5 wt.% to about 5 wt.% of the total components of the composition.Embodiment 86. The pharmaceutical composition of any one of embodiments 83-85, wherein the pharmaceutical composition comprises the lubricant in an amount of from about 0.5 wt.% to about 3 wt.% of the total components of the composition.Embodiment 87. The pharmaceutical composition of any one of embodiments 83-85, wherein the pharmaceutical composition comprises the lubricant in an amount of about 1 wt.% of the total components of the composition.Embodiment 88. A pharmaceutical composition comprising:(i) celastrol;(ii) copovidone;(iii) microcrystalline cellulose (MCC);(iv) a 3 : 1 mixture of alpha lactose monohydrate and powdered cellulose;(v) hydroxypropyl cellulose (HPC);(vi) sodium carboxymethyl starch (CMS-Na); and(vii) magnesium stearate.Embodiment 89. A pharmaceutical composition comprising:(i) celastrol in an amount of from about 0.5 wt.% to about 5 wt.% of the total components of the composition, optionally about 4 wt.% of the total components of the composition, optionally in an amount of about 2 wt.% of the total components of the composition;Attorney Docket No.: 045898-510001WO(ii) copovidone in an amount of from about 2 wt.% to about 10 wt.% of the total components of the composition, optionally about 6 wt.% of the total components of the composition;(iii) microcrystalline cellulose (MCC) in an amount of from about 60 wt.% to about 75% of the total components of the composition, optionally about 67 wt.% of the total components of the composition;(iv) a 3 : 1 mixture of alpha lactose monohydrate and powdered cellulose in an amount of from about 10 wt.% to about 25 wt.% of the total components of the composition, optionally about 17 wt.% of the total components of the composition;(v) hydroxypropyl cellulose (HPC) in an amount of from about 0.5 wt.% to about 5% of the total components of the composition, optionally about 2% of the total components of the composition;(vi) sodium carboxymethyl starch (CMS-Na) in an amount of from about 0.5 wt.% to about 10% of the total components of the composition, optionally about 5% of the total components of the composition; and(vii) magnesium stearate in an amount of from about 0.5 wt.% to about 5 wt.% of the total components of the composition.Embodiment 90. A pharmaceutical composition comprising:(i) celastrol in an amount of about 2 wt.% of the total components of the composition; (ii) copovidone in an amount of from about 6 wt.% of the total components of the composition;(iii) microcrystalline cellulose (MCC) in an amount of about 67 wt.% of the total components of the composition;(iv) a 3 : 1 mixture of alpha lactose monohydrate and powdered cellulose in an amount of about 17 wt.% of the total components of the composition;(v) hydroxypropyl cellulose (HPC) in an amount of about 2% of the total components of the composition;(vi) sodium carboxymethyl starch (CMS-Na) in an amount of about 5% of the total components of the composition; andAttorney Docket No.: 045898-510001WO(vii) magnesium stearate in an amount of about 1 wt.% of the total components of the composition.Embodiment 91. A pharmaceutical composition comprising:(i) celastrol in an amount of about 4 wt.% of the total components of the composition; (ii) copovidone in an amount of from about 6 wt.% of the total components of the composition;(iii) microcrystalline cellulose (MCC) in an amount of about 67 wt.% of the total components of the composition;(iv) a 3 : 1 mixture of alpha lactose monohydrate and powdered cellulose in an amount of about 17 wt.% of the total components of the composition;(v) hydroxypropyl cellulose (HPC) in an amount of about 2% of the total components of the composition;(vi) sodium carboxymethyl starch (CMS-Na) in an amount of about 5% of the total components of the composition; and(vii) magnesium stearate in an amount of about 1 wt.% of the total components of the composition.Embodiment 92. The pharmaceutical composition of any one of embodiments 35-91, wherein the pharmaceutical composition is in the form of a tablet.Embodiment 93. The pharmaceutical composition of embodiment 92, wherein the tablet comprises celastrol in an amount of about 2 mg.Embodiment 94. The pharmaceutical composition of embodiment 92, wherein the tablet comprises celastrol in an amount of about 4 mg.Embodiment 95. The pharmaceutical composition of any one of embodiments 92-94, wherein the tablet has a weight of about 100 mg.Embodiment 96. The pharmaceutical composition of any one of embodiments 92-95, wherein the tablet further comprises an enteric coating.Embodiment 97. The pharmaceutical composition of any one of embodiments 92-95, wherein the tablet further comprises a film coating.Attorney Docket No.: 045898-510001WOEmbodiment 98. The pharmaceutical composition of embodiment 97, wherein the coating is a gastric soluble coating.Embodiment 99. The pharmaceutical composition of any one of embodiments 96-98, wherein the coating comprises talc, glyceryl monocaprylocaprate, and polyvinyl alcohol. Embodiment 100. The pharmaceutical composition of any one of embodiments 96-98, wherein the coating comprises hypromellose, lactose monohydrate, titanium dioxide, and polyethylene glycol.Embodiment 101. The pharmaceutical composition of any one of embodiments 96-98, wherein the coating comprises talc, glyceryl monocaprylocaprate, sodium lauryl sulfate, and polyvinyl alcohol.Embodiment 102. The pharmaceutical composition of any one of embodiments 96-98, wherein the coating comprises talc, glyceryl monocaprylocaprate, polyvinyl alcohol graft polymer, titanium dioxide, polyethylene glycol, and polyvinyl alcohol.Embodiment 103. The pharmaceutical composition of any one of embodiments 96-98, wherein the coating comprises partially hydrolyzed polyvinyl alcohol, Glyceryl monocaprylocaprate, Type I, macrogol(PEG) polyvinyl alcohol graft copolymer, titanium dioxide, talc, ferric oxide yellow, and ferrosoferric oxide / black iron oxide.Embodiment 104. The pharmaceutical composition of any one of embodiments 96-98, wherein the coating comprises partially hydrolyzed polyvinyl alcohol, titanium dioxide, talc, ferric oxide yellow, and ferrosoferric oxide / black iron oxide.Embodiment 105. The pharmaceutical composition of any one of embodiments 96-98, wherein the coating comprises hydroxypropyl methyl cellulose, macrogol(PEG), titanium dioxide, and ferric oxide yellow.Embodiment 106. The pharmaceutical composition of any one of embodiments 99-105, wherein the coating further comprises a pigment.Embodiment 107. The pharmaceutical composition of any one of embodiments 99-105, wherein the coating further comprises Fe(OH)3.Embodiment 108. The pharmaceutical composition of any one of embodiments 96-107, wherein the tablet comprises the coating in an amount of from about 3% to about 5% of the total weight of the tablet.Attorney Docket No.: 045898-510001WOEmbodiment 109. The pharmaceutical composition of any one of embodiments 96-107, wherein the tablet comprises the coating in an amount of about 4% of the total weight of the tablet.Embodiment 110. The pharmaceutical composition of any one of embodiments 96-107, wherein the tablet comprises the coating in an amount of about 3.8% of the total weight of the tablet.Embodiment 111. The pharmaceutical composition of any one of embodiments 96-107, wherein the total weight of the tablet including the coating is about 104 mg.Embodiment 112. The pharmaceutical composition of embodiment 111, wherein the tablet is soluble in an aqueous solvent.Embodiment 113. The pharmaceutical composition of embodiment 112, wherein the aqueous solvent has a pH of about 7.Embodiment 114. The pharmaceutical composition of embodiment 112 or 113, wherein the aqueous solvent comprises a sodium phosphate buffer.Embodiment 115. The pharmaceutical composition of any one of embodiments 112-114, wherein the aqueous solvent comprises sodium dodecyl sulfate (SDS).Embodiment 116. The pharmaceutical composition of embodiment 112-115, wherein at least 90% of the tablet dissolves within about 20 min.Embodiment 117. The pharmaceutical composition of any one of embodiments 112-116, wherein at least 95% of the tablet dissolves within about 20 min.Embodiment 118. The liquid formulation, amorphous solid dispersion, or pharmaceutical composition of any one of embodiments 1-117, wherein the celastrol is in amorphous form. Embodiment 119. The liquid formulation, amorphous solid dispersion, or pharmaceutical composition of any one of embodiments 1-117, wherein the celastrol is in the form of a polymorph.Embodiment 120. A process for making a pharmaceutical composition comprising celastrol comprising:Step a): Mixing a polymorph of celastrol with a solvent to yield mixture 1;Step b): Adding a polymer to mixture 1 to yield mixture 2; andAttorney Docket No.: 045898-510001WOStep c): Spray-drying mixture 2 to yield an amorphous solid dispersion.Embodiment 121. A process for making a pharmaceutical composition comprising celastrol comprising:Step a’): Mixing a polymorph of celastrol and a polymer with a solvent to yield mixture la; andStep b’): Spray-drying mixture la to yield an amorphous solid dispersion.Embodiment 122. The process of embodiment 120 or 121, wherein the solvent is an alcohol.Embodiment 123. The process of embodiment 122, wherein the alcohol is methanol. Embodiment 124. The process of embodiment 120 or 121, wherein the solvent is acetone Embodiment 125. The process of any one of embodiments 120-124, wherein the polymer is hydroxypropyl methylcellulose acetate succinate (HPMCAS).Embodiment 126. The process of any one of embodiments 120-124, wherein the polymer is a water-soluble polymer.Embodiment 127. The process of embodiment 126, wherein the water-soluble polymer is hydroxypropyl methylcellulose phthalate (HPMCP).Embodiment 128. The process of embodiment 126, wherein the water-soluble polymer comprises 1 -vinyl -2-pyrrolidone monomers.Embodiment 129. The process of embodiment 126, wherein the water-soluble polymer comprises 1 -vinyl -2-pyrrolidone monomers and vinyl acetate monomers.Embodiment 130. The process of embodiment 126, wherein the water-soluble polymer is copovidone.Embodiment 131. The process of embodiment 126, wherein the water-soluble polymer is povidone.Embodiment 132. The process of embodiment 126, wherein the water-soluble polymer comprises caprolactam monomers, polyvinyl acetate monomers, and polyethylene glycol monomers.Embodiment 133. The process of embodiment 132, wherein the water-soluble polymer is a polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer.Attorney Docket No.: 945898-519991WOEmbodiment 134. The process of embodiment 133, wherein the water-soluble polymer comprises polyethylene glycol 6000 (PEG 6000), vinylcaprolactam and vinyl acetate at a wt / wt / wt. ratio of about 13:57:30.Embodiment 135. The process of embodiment 126, wherein the water-soluble polymer comprises acrylic acid monomers.Embodiment 136. The process of embodiment 135, wherein the water-soluble polymer is a polymethacrylate.Embodiment 137. The process of embodiment 135, wherein the water-soluble polymer is a co-polymer comprising methacrylic acid monomers and methyl methacrylate monomers at a monomer ratio of about 1 :2.Embodiment 138. The process of embodiment 135, wherein the water-soluble polymer is an anionic co-polymer comprising methacrylic acid monomers and methyl methacrylate monomers at a monomer ratio of about 1:1.Embodiment 139. The process of embodiment 135, wherein the water-soluble polymer is a poly(methacrylic acid-co-methyl methacrylate).Embodiment 140. The process, liquid formulation, amorphous solid dispersion, or pharmaceutical composition of any one of embodiments 119-139, wherein the polymorph of celastrol is a crystalline Form III of celastrol, wherein the crystalline Form III of celastrol is characterized by an X-ray powder diffraction pattern comprising peaks at 29 angles (±0.2) selected from the group consisting of 9.51°, 14.81°, and 16.84°.Embodiment 141. The process, liquid formulation, amorphous solid dispersion, or pharmaceutical composition of embodiment any one of embodiments 119-139, wherein the polymorph of celastrol is a crystalline Form III of celastrol, wherein the crystalline Form III of celastrol is characterized by an X-ray powder diffraction pattern further comprising one or more peaks at 29 angles (±9.2) selected from the group consisting of 13.69°, 14.65°, 18.74°, and 19.19°.Embodiment 142. The process, liquid formulation, amorphous solid dispersion, or pharmaceutical composition of any one of embodiments 119-141, wherein the crystalline Form III of celastrol is characterized by an X-ray powder diffraction pattern that is substantially the same as Figure 1.Attorney Docket No.: 045898-510001WOEmbodiment 143. The process, liquid formulation, amorphous solid dispersion, or pharmaceutical composition of any one of embodiments 119-142, wherein the crystalline Form III of celastrol is characterized by a differential scanning calorimetry (DSC) profile with no endothermic peak and an exothermic peak at about 215 °C (onset).Embodiment 144. The process, liquid formulation, amorphous solid dispersion, or pharmaceutical composition of any one of embodiments 119-143, wherein the crystalline Form III of celastrol is characterized by thermal gravimetric analysis (TGA) profile with about 0.5% weight loss at about the exothermic peak at about 215 °C (onset).Embodiment 145. The process, liquid formulation, amorphous solid dispersion, or pharmaceutical composition of any one of embodiments 119-144, wherein the crystalline Form III of celastrol comprises about 5000 ppm or less of n-heptane.Embodiment 146. The process, liquid formulation, amorphous solid dispersion, or pharmaceutical composition of any one of embodiments 119-144, wherein the crystalline Form III of celastrol comprises about 70 ppm or less of n-heptane.Embodiment 147. The process, liquid formulation, amorphous solid dispersion, or pharmaceutical composition of any one of embodiments 119-145, wherein the crystalline form comprises about 5000 ppm or less of 2-methyltetrahydrofuran.Embodiment 148. The process, liquid formulation, amorphous solid dispersion, or pharmaceutical composition of any one of embodiments 119-145, wherein the crystalline form comprises about 500 ppm or less of 2-methyltetrahydrofuran.Embodiment 149. The process, liquid formulation, amorphous solid dispersion, or pharmaceutical composition of any one of embodiments 119-147, wherein the crystalline form comprises about 5000 ppm or less of ethyl acetate.Embodiment 150. The process, liquid formulation, amorphous solid dispersion, or pharmaceutical composition of any one of embodiments 119-147, wherein the crystalline form comprises about 10 ppm or less of ethyl acetate.Embodiment 151. The process, liquid formulation, amorphous solid dispersion, or pharmaceutical composition of any one of embodiments 119-149, wherein the crystalline Form III of celastrol comprises about 3,000 ppm or less of methanol.Attorney Docket No.: 045898-510001WOEmbodiment 152. The process, liquid formulation, amorphous solid dispersion, or pharmaceutical composition of any one of embodiments 119-149, wherein the crystalline Form III of celastrol comprises about 1,500 ppm or less of methanol.Embodiment 153. The process, liquid formulation, amorphous solid dispersion, or pharmaceutical composition of any one of embodiments 119-151, wherein the crystalline Form III of celastrol comprises about 5000 ppm or less of ethanol.Embodiment 154. The process, liquid formulation, amorphous solid dispersion, or pharmaceutical composition of any one of embodiments 119-151, wherein the crystalline Form III of celastrol comprises about 600 ppm or less of ethanol.Embodiment 155. The process, liquid formulation, amorphous solid dispersion, or pharmaceutical composition of any one of embodiments 119-154, wherein the crystalline Form III of celastrol is free of methanol, ethanol, and / or dichloromethane.Embodiment 156. The process, liquid formulation, amorphous solid dispersion, or pharmaceutical composition of any one of embodiments 119-155, wherein the crystalline Form III of celastrol has at least 99.8% purity.Embodiment 157. The process, liquid formulation, amorphous solid dispersion, or pharmaceutical composition of any one of embodiments 119-156, wherein the crystalline Form III of celastrol is anhydrous.EQUIVALENTS

[0121] Those skilled in the art will recognize, or be able to ascertain, using no more than routine experimentation, numerous equivalents to the specific embodiments described specifically herein. Such equivalents are intended to be encompassed in the scope of the following claims. All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference.

Claims

Attorney Docket No.: 045898-510001WOCLAIMS1. A pharmaceutical composition comprising:(i) celastrol in an amount of from about 0.5 wt.% to about 5 wt.% of the total components of the composition, optionally about 4 wt.% of the total components of the composition, optionally about 2 wt.% of the total components of the composition; (ii) copovidone in an amount of from about 2 wt.% to about 10 wt.% of the total components of the composition, optionally about 6 wt.% of the total components of the composition;(iii) microcrystalline cellulose (MCC) in an amount of from about 60 wt.% to about 75% of the total components of the composition, optionally about 67 wt.% of the total components of the composition;(iv) a 3 : 1 mixture of alpha lactose monohydrate and powdered cellulose in an amount of from about 10 wt.% to about 25 wt.% of the total components of the composition, optionally about 17 wt.% of the total components of the composition;(v) hydroxypropyl cellulose (HPC) in an amount of from about 0.5 wt.% to about 5% of the total components of the composition, optionally about 2% of the total components of the composition;(vi) sodium carboxymethyl starch (CMS-Na) in an amount of from about 0.5 wt.% to about 10% of the total components of the composition, optionally about 5% of the total components of the composition; and(vii) magnesium stearate in an amount of from about 0.5 wt.% to about 5 wt.% of the total components of the composition.

2. A liquid formulation comprising:(i) celastrol;(ii) a polymer; and(iii) a solvent.

3. The liquid formulation of claim 2, wherein the solvent is an alcohol.

4. The liquid formulation of claim 2, wherein the alcohol is methanol.

5. The liquid formulation of claim 2, wherein the solvent is acetone.Attorney Docket No.: 045898-510001WO6. The liquid formulation of any one of claims 2-5, wherein the concentration of celastrol in the liquid formulation is from about 10 mg / mL to about 20 mg / mL.

7. The liquid formulation of any one of claims 2-5, wherein the concentration of celastrol in the liquid formulation is about 15 mg / mL.

8. The liquid formulation of any one of claims 2-7, wherein the concentration of the polymer in the liquid formulation is from about 30 mg / mL to about 70 mg / mL.

9. The liquid formulation of any one of claims 2-7, wherein the concentration of the polymer in the liquid formulation is from about 40 mg / mL to about 50 mg / mL.

10. The liquid formulation of any one of claims 2-7, wherein the concentration of the polymer in the liquid formulation is about 45 mg / mL.

11. The liquid formulation of any one of claims 2-7, wherein the concentration of the polymer in the liquid formulation is from about 50 mg / mL to about 70 mg / mL.

12. The liquid formulation of any one of claims 2-7, wherein the concentration of the polymer in the liquid formulation is from about 55 mg / mL to about 65 mg / mL.

13. The liquid formulation of any one of claims 2-7, wherein the concentration of the polymer in the liquid formulation is about 60 mg / mL.

14. The liquid formulation of any one of claims 2-13, wherein the liquid formulation is for preparing an amorphous solid dispersion.

15. The liquid formulation of any one of claims 2-14, wherein the liquid formulation is for preparing an amorphous solid dispersion by spray drying the liquid formulation.

16. A method for preparing an amorphous solid dispersion comprising spray drying the liquid formulation of any one of claims 2-15.

17. An amorphous solid dispersion comprising:(i) celastrol; and(ii) a polymer.

18. The amorphous solid dispersion of claim 17, wherein the amorphous solid dispersion is made by spray drying liquid formulation of any one of claims 2-15.

19. The liquid formulation or amorphous solid dispersion of any one of claims 2-18, comprising the celastrol and the polymer at a wt / wt ratio of from about 1 :5 to about 1:1.Attorney Docket No.: 045898-510001WO20. The liquid formulation or amorphous solid dispersion of any one of claims 2-19, comprising the celastrol and the polymer at a wt / wt ratio of about 1 :3.

21. The liquid formulation or amorphous solid dispersion of any one of claims 2-20, wherein the polymer is hydroxypropyl methylcellulose acetate succinate (HPMCAS).

22. The liquid formulation or amorphous solid dispersion of any one of claims 2-20, wherein the polymer is a water-soluble polymer.

23. The liquid formulation or amorphous solid dispersion of claim 22, wherein the water- soluble polymer is hydroxypropyl methylcellulose phthalate (HPMCP).

24. The liquid formulation or amorphous solid dispersion of claim 22, wherein the water- soluble polymer comprises l-vinyl-2-pyrrolidone monomers.

25. The liquid formulation or amorphous solid dispersion of claim 22, wherein the water- soluble polymer comprises l-vinyl-2-pyrrolidone monomers and vinyl acetate monomers.

26. The liquid formulation or amorphous solid dispersion of claim 22, wherein the water- soluble polymer is copovidone.

27. The liquid formulation or amorphous solid dispersion of claim 22, wherein the water- soluble polymer is povidone.

28. The liquid formulation or amorphous solid dispersion of claim 22, wherein the water- soluble polymer comprises caprolactam monomers, polyvinyl acetate monomers, and polyethylene glycol monomers.

29. The liquid formulation or amorphous solid dispersion of claim 28, wherein the water- soluble polymer is a polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer.

30. The liquid formulation or amorphous solid dispersion of claim 28, wherein the water- soluble polymer comprises polyethylene glycol 6000 (PEG 6000), vinylcaprolactam and vinyl acetate at a wt. / wt. / wt. ratio of about 13:57:30.

31. The liquid formulation or amorphous solid dispersion of claim 22, wherein the water- soluble polymer comprises acrylic acid monomers.

32. The liquid formulation or amorphous solid dispersion of claim 31, wherein the water- soluble polymer is a polymethacrylate.Attorney Docket No.: 045898-510001WO33. The liquid formulation or amorphous solid dispersion of claim 31, wherein the water- soluble polymer is a co-polymer comprising methacrylic acid monomers and methyl methacrylate monomers at a monomer ratio of about 1 :2.

34. The liquid formulation or amorphous solid dispersion of claim 31, wherein the water- soluble polymer is an anionic co-polymer comprising methacrylic acid monomers and methyl methacrylate monomers at a monomer ratio of about 1:1.

35. The liquid formulation or amorphous solid dispersion of claim 31, wherein the water- soluble polymer is a poly(methacrylic acid-co-methyl methacrylate).

36. A pharmaceutical composition comprising the amorphous solid dispersion of any one of claims 17-35.

37. A pharmaceutical composition comprising celastrol and a polymer.

38. The pharmaceutical composition of claim 37, wherein celastrol is present in an amount of from about 0.5 wt.% to about 5 wt.% of the total components of the composition.

39. The pharmaceutical composition of claim 37, wherein celastrol is present in an amount of about 4 wt.% of the total components of the composition.

40. The pharmaceutical composition of claim 37, wherein celastrol is present in an amount of about 2 wt.% of the total components of the composition.

41. The pharmaceutical composition of any one of claims 37-40, wherein the polymer is hydroxypropyl methylcellulose acetate succinate (HPMCAS).

42. The pharmaceutical composition of any one of claims 37-40, wherein the polymer is a water-soluble polymer.

43. The pharmaceutical composition of claim 42, wherein the water-soluble polymer is hydroxypropyl methylcellulose phthalate (HPMCP).

44. The pharmaceutical composition of claim 42, wherein the water-soluble polymer comprises 1 -vinyl -2-pyrrolidone monomers.

45. The pharmaceutical composition of claim 42, wherein the water-soluble polymer comprises 1 -vinyl -2-pyrrolidone monomers and vinyl acetate monomers.

46. The pharmaceutical composition of claim 42, wherein the water-soluble polymer is copovidone.Attorney Docket No.: 045898-510001WO47. The pharmaceutical composition of claim 42, wherein the water-soluble polymer is povidone.

48. The pharmaceutical composition of claim 42, wherein the water-soluble polymer comprises caprolactam monomers, polyvinyl acetate monomers, and polyethylene glycol monomers.

49. The pharmaceutical composition of claim 48, wherein the water-soluble polymer is a polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer.

50. The pharmaceutical composition of claim 49, wherein the water-soluble polymer comprises polyethylene glycol 6000 (PEG 6000), vinylcaprolactam and vinyl acetate at a wt / wt / wt. ratio of about 13:57:30.

51. The pharmaceutical composition of claim 42, wherein the water-soluble polymer comprises acrylic acid monomers.

52. The pharmaceutical composition of claim 51, wherein the water-soluble polymer is a polymethacrylate.

53. The pharmaceutical composition of claim 51, wherein the water-soluble polymer is a co-polymer comprising methacrylic acid monomers and methyl methacrylate monomers at a monomer ratio of about 1 :2.

54. The pharmaceutical composition of claim 51, wherein the water-soluble polymer is an anionic co-polymer comprising methacrylic acid monomers and methyl methacrylate monomers at a monomer ratio of about 1:1.

55. The pharmaceutical composition of claim 51, wherein the water-soluble polymer is a poly(methacrylic acid-co-methyl methacrylate).

56. The pharmaceutical composition of any one of claims 30-55, comprising the polymer in an amount of from about 2 wt.% to about 10 wt.% of the total components of the composition.

57. The pharmaceutical composition of any one of claims 30-55, comprising the polymer in an amount of about 6 wt.% of the total components of the composition.

58. The pharmaceutical composition of any one of claims 30-56, further comprising a filler.Attorney Docket No.: 045898-510001WO59. The pharmaceutical composition of claim 58, wherein the pharmaceutical composition comprises the filler in an amount of from about 75 wt.% to about 85 wt.% of the total components of the composition.

60. The pharmaceutical composition of claim 58, wherein the pharmaceutical composition comprises the filler in an amount of from about 80 wt.% to about 90 wt.% of the total components of the composition.

61. The pharmaceutical composition of claim 58, wherein the pharmaceutical composition comprises the filler in an amount of about 84 wt.% of the total components of the composition.

62. The pharmaceutical composition of any one of claims 58-61, wherein the filler is selected from one or more of microcrystalline cellulose (MCC), a mixture of alpha lactose monohydrate and powdered cellulose, and mannitol.

63. The pharmaceutical composition of any one of claims 58-61, wherein the filler comprises microcrystalline cellulose (MCC).

64. The pharmaceutical composition of any one of claims 58-61, wherein the pharmaceutical composition comprises microcrystalline cellulose (MCC) in an amount of from about 60 wt.% to about 75% of the total components of the composition.

65. The pharmaceutical composition of any one of claims 58-61, wherein the pharmaceutical composition comprises microcrystalline cellulose (MCC) in an amount of about 67 wt.% of the total components of the composition.

66. The pharmaceutical composition of any one of claims 58-65, wherein the filler comprises a mixture of alpha lactose monohydrate and powdered cellulose.

67. The pharmaceutical composition of any one of claims 58-65, wherein the filler comprises a mixture of alpha lactose monohydrate and powdered cellulose at a ratio of about 3:1.

68. The pharmaceutical composition of any one of claims 58-67, wherein the pharmaceutical composition comprises the mixture of alpha lactose monohydrate and powdered cellulose in an amount of from about 10 wt.% to about 25 wt.% of the total components of the composition.

69. The pharmaceutical composition of any one of claims 58-67, wherein the pharmaceutical composition comprises the mixture of alpha lactose monohydrate andAttorney Docket No.: 045898-510001WOpowdered cellulose in an amount of about 17 wt.% of the total components of the composition.

70. The pharmaceutical composition of any one of claims 58-61, wherein the filler comprises microcrystalline cellulose (MCC) and a mixture of alpha lactose monohydrate and powdered cellulose.

71. The pharmaceutical composition of any one of claims 35-69, further comprising a binder.

72. The pharmaceutical composition of claim 71, wherein the binder is hydroxypropyl cellulose (HPC).

73. The pharmaceutical composition of claim 71 or 72, wherein the pharmaceutical composition comprises the binder in an amount of from about 0.5 wt.% to about 5% of the total components of the composition.

74. The pharmaceutical composition of claim 71 or 72, wherein the pharmaceutical composition comprises the binder in an amount of about 2 wt.% of the total components of the composition.

75. The pharmaceutical composition of any one of claims 35-74, further comprising a disintegrant.

76. The pharmaceutical composition of claim 75, wherein the disintegrant comprises one or more of sodium starch glycolate (SSG), sodium carboxymethyl starch (CMS-Na), or polyvinylpolypyrrolidone (crospovidone).

77. The pharmaceutical composition of claim 75, wherein the disintegrant is polyvinylpolypyrrolidone (crospovidone).

78. The pharmaceutical composition of claim 75, wherein the disintegrant is sodium starch glycolate (SSG).

79. The pharmaceutical composition of claim 75, wherein the disintegrant is sodium carb oxy methyl starch (CMS-Na).

80. The pharmaceutical composition of any one of claims 75-79, wherein the pharmaceutical composition comprises the disintegrant in an amount of from about 0.5 wt.% to about 10% of the total components of the composition.Attorney Docket No.: 045898-510001WO81. The pharmaceutical composition of any one of claims 75-79, wherein the pharmaceutical composition comprises the disintegrant in an amount of from about 2 wt.% to about 8% of the total components of the composition.

82. The pharmaceutical composition of any one of claims 75-79, wherein the pharmaceutical composition comprises the disintegrant in an amount of about 5 wt.% of the total components of the composition.

83. The pharmaceutical composition of any one of claims 35-82, further comprising a lubricant.

84. The pharmaceutical composition of claim 83, wherein the lubricant is sodium stearyl fumarate.

85. The pharmaceutical composition of claim 83, wherein the lubricant is magnesium stearate.

86. The pharmaceutical composition of any one of claims 83-85, wherein the pharmaceutical composition comprises the lubricant in an amount of from about 0.5 wt.% to about 5 wt.% of the total components of the composition.

87. The pharmaceutical composition of any one of claims 83-85, wherein the pharmaceutical composition comprises the lubricant in an amount of from about 0.5 wt.% to about 3 wt.% of the total components of the composition.

88. The pharmaceutical composition of any one of claims 83-85, wherein the pharmaceutical composition comprises the lubricant in an amount of about 1 wt.% of the total components of the composition.

89. A pharmaceutical composition comprising:(i) celastrol;(ii) copovidone;(iii) microcrystalline cellulose (MCC);(iv) a 3 : 1 mixture of alpha lactose monohydrate and powdered cellulose;(v) hydroxypropyl cellulose (HPC);(vi) sodium carboxymethyl starch (CMS-Na); and(vii) magnesium stearate.Attorney Docket No.: 045898-510001WO90. A pharmaceutical composition comprising:(i) celastrol in an amount of about 2 wt.% of the total components of the composition; (ii) copovidone in an amount of from about 6 wt.% of the total components of the composition;(iii) microcrystalline cellulose (MCC) in an amount of about 67 wt.% of the total components of the composition;(iv) a 3 : 1 mixture of alpha lactose monohydrate and powdered cellulose in an amount of about 17 wt.% of the total components of the composition;(v) hydroxypropyl cellulose (HPC) in an amount of about 2% of the total components of the composition;(vi) sodium carboxymethyl starch (CMS-Na) in an amount of about 5% of the total components of the composition; and(vii) magnesium stearate in an amount of about 1 wt.% of the total components of the composition.

91. A pharmaceutical composition comprising:(i) celastrol in an amount of about 4 wt.% of the total components of the composition; (ii) copovidone in an amount of from about 6 wt.% of the total components of the composition;(iii) microcrystalline cellulose (MCC) in an amount of about 67 wt.% of the total components of the composition;(iv) a 3 : 1 mixture of alpha lactose monohydrate and powdered cellulose in an amount of about 17 wt.% of the total components of the composition;(v) hydroxypropyl cellulose (HPC) in an amount of about 2% of the total components of the composition;(vi) sodium carboxymethyl starch (CMS-Na) in an amount of about 5% of the total components of the composition; and(vii) magnesium stearate in an amount of about 1 wt.% of the total components of the composition.Attorney Docket No.: 045898-510001WO92. The pharmaceutical composition of any one of claims 35-91, wherein the pharmaceutical composition is in the form of a tablet.

93. The pharmaceutical composition of claim 92, wherein the tablet comprises celastrol in an amount of about 2 mg.

94. The pharmaceutical composition of claim 92, wherein the tablet comprises celastrol in an amount of about 4 mg.

95. The pharmaceutical composition of any one of claims 92-94, wherein the tablet has a weight of about 100 mg.

96. The pharmaceutical composition of any one of claims 92-95, wherein the tablet further comprises an enteric coating.

97. The pharmaceutical composition of any one of claims 92-95, wherein the tablet further comprises a film coating.

98. The pharmaceutical composition of claim 97, wherein the coating is a gastric soluble coating.

99. The pharmaceutical composition of any one of claims 96-98, wherein the coating comprises talc, glyceryl monocaprylocaprate, and polyvinyl alcohol.

100. The pharmaceutical composition of any one of claims 96-98, wherein the coating comprises hypromellose, lactose monohydrate, titanium dioxide, and polyethylene glycol.

101. The pharmaceutical composition of any one of claims 96-98, wherein the coating comprises talc, glyceryl monocaprylocaprate, sodium lauryl sulfate, and polyvinyl alcohol.

102. The pharmaceutical composition of any one of claims 96-98, wherein the coating comprises talc, glyceryl monocaprylocaprate, polyvinyl alcohol graft polymer, titanium dioxide, polyethylene glycol, and polyvinyl alcohol.

103. The pharmaceutical composition of any one of claims 96-98, wherein the coating comprises partially hydrolyzed polyvinyl alcohol, glyceryl monocaprylocaprate, Type I, macrogol(PEG) polyvinyl alcohol graft copolymer, titanium dioxide, talc, ferric oxide yellow, and ferrosoferric oxide / black iron oxide.Attorney Docket No.: 045898-510001WO104. The pharmaceutical composition of any one of claims 96-98, wherein the coating comprises partially hydrolyzed polyvinyl alcohol, titanium dioxide, talc, ferric oxide yellow, and ferrosoferric oxide / black iron oxide.

105. The pharmaceutical composition of any one of claims 96-98, wherein the coating comprises hydroxypropyl methyl cellulose, macrogol(PEG), titanium dioxide, and ferric oxide yellow.

106. The pharmaceutical composition of any one of claims 99-105, wherein the coating further comprises a pigment.

107. The pharmaceutical composition of any one of claims 99-105, wherein the coating further comprises Fe(OH)3.

108. The pharmaceutical composition of any one of claims 96-107, wherein the tablet comprises the coating in an amount of from about 3% to about 5% of the total weight of the tablet.

109. The pharmaceutical composition of any one of claims 96-107, wherein the tablet comprises the coating in an amount of about 4% of the total weight of the tablet.

110. The pharmaceutical composition of any one of claims 96-107, wherein the tablet comprises the coating in an amount of about 3.8% of the total weight of the tablet.

111. The pharmaceutical composition of any one of claims 96-107, wherein the total weight of the tablet including the coating is about 104 mg.

112. The pharmaceutical composition of claim 111, wherein the tablet is soluble in an aqueous solvent.

113. The pharmaceutical composition of claim 112, wherein the aqueous solvent has a pH of about 7.

114. The pharmaceutical composition of claim 112 or 113, wherein the aqueous solvent comprises a sodium phosphate buffer.

115. The pharmaceutical composition of any one of claims 112-114, wherein the aqueous solvent comprises sodium dodecyl sulfate (SDS).

116. The pharmaceutical composition of claim 112-115, wherein at least 90% of the tablet dissolves within about 20 min.Attorney Docket No.: 045898-510001WO117. The pharmaceutical composition of any one of claims 112-116, wherein at least 95% of the tablet dissolves within about 20 min.

118. The liquid formulation, amorphous solid dispersion, or pharmaceutical composition of any one of claims 1-117, wherein the celastrol is in amorphous form.

119. The liquid formulation, amorphous solid dispersion, or pharmaceutical composition of any one of claims 1-117, wherein the celastrol is in the form of a polymorph.

120. A process for making a pharmaceutical composition comprising celastrol comprising:Step a): Mixing a polymorph of celastrol with a solvent to yield mixture 1;Step b): Adding a polymer to mixture 1 to yield mixture 2; andStep c): Spray-drying mixture 2 to yield an amorphous solid dispersion.

121. A process for making a pharmaceutical composition comprising celastrol comprising:Step a’): Mixing a polymorph of celastrol and a polymer with a solvent to yield mixture la; andStep b’): Spray-drying mixture la to yield an amorphous solid dispersion.

122. The process of claim 120 or 121, wherein the solvent is an alcohol.

123. The process of claim 122, wherein the alcohol is methanol.

124. The process of claim 120 or 121, wherein the solvent is acetone125. The process of any one of claims 120-124, wherein the polymer is hydroxypropyl methylcellulose acetate succinate (HPMCAS).

126. The process of any one of claims 120-124, wherein the polymer is a water-soluble polymer.

127. The process of claim 126, wherein the water-soluble polymer is hydroxypropyl methylcellulose phthalate (HPMCP).

128. The process of claim 126, wherein the water-soluble polymer comprises l-vinyl-2- pyrrolidone monomers.

129. The process of claim 126, wherein the water-soluble polymer comprises l-vinyl-2- pyrrolidone monomers and vinyl acetate monomers.

130. The process of claim 126, wherein the water-soluble polymer is copovidone.Attorney Docket No.: 045898-510001WO131. The process of claim 126, wherein the water-soluble polymer is povidone.

132. The process of claim 126, wherein the water-soluble polymer comprises caprolactam monomers, polyvinyl acetate monomers, and polyethylene glycol monomers.

133. The process of claim 132, wherein the water-soluble polymer is a polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer.

134. The process of claim 133, wherein the water-soluble polymer comprises polyethylene glycol 6000 (PEG 6000), vinylcaprolactam and vinyl acetate at a wt / wt / wt. ratio of about 13:57:30.

135. The process of claim 126, wherein the water-soluble polymer comprises acrylic acid monomers.

136. The process of claim 135, wherein the water-soluble polymer is a polymethacrylate.

137. The process of claim 135, wherein the water-soluble polymer is a co-polymer comprising methacrylic acid monomers and methyl methacrylate monomers at a monomer ratio of about 1 :2.

138. The process of claim 135, wherein the water-soluble polymer is an anionic co-polymer comprising methacrylic acid monomers and methyl methacrylate monomers at a monomer ratio of about 1:1.

139. The process of claim 135, wherein the water-soluble polymer is a poly(methacrylic acid-co-methyl methacrylate).

140. The process, liquid formulation, amorphous solid dispersion, or pharmaceutical composition of any one of claims 119-139, wherein the polymorph of celastrol is a crystalline Form III of celastrol, wherein the crystalline Form III of celastrol is characterized by an X-ray powder diffraction pattern comprising peaks at 29 angles (±0.2) selected from the group consisting of 9.51°, 14.81°, and 16.84°.

141. The process, liquid formulation, amorphous solid dispersion, or pharmaceutical composition of claim any one of claims 119-139, wherein the polymorph of celastrol is a crystalline Form III of celastrol, wherein the crystalline Form III of celastrol is characterized by an X-ray powder diffraction pattern further comprising one or more peaks at 29 angles (±0.2) selected from the group consisting of 13.60°, 14.65°, 18.74°, and 19.10°.Attorney Docket No.: 045898-510001WO142. The process, liquid formulation, amorphous solid dispersion, or pharmaceutical composition of any one of claims 119-141, wherein the crystalline Form III of celastrol is characterized by an X-ray powder diffraction pattern that is substantially the same as Figure 1.

143. The process, liquid formulation, amorphous solid dispersion, or pharmaceutical composition of any one of claims 119-142, wherein the crystalline Form III of celastrol is characterized by a differential scanning calorimetry (DSC) profile with no endothermic peak and an exothermic peak at about 215 °C (onset).

144. The process, liquid formulation, amorphous solid dispersion, or pharmaceutical composition of any one of claims 119-143, wherein the crystalline Form III of celastrol is characterized by thermal gravimetric analysis (TGA) profile with about 0.5% weight loss at about the exothermic peak at about 215 °C (onset).

145. The process, liquid formulation, amorphous solid dispersion, or pharmaceutical composition of any one of claims 119-144, wherein the crystalline Form III of celastrol comprises about 5000 ppm or less of n-heptane.

146. The process, liquid formulation, amorphous solid dispersion, or pharmaceutical composition of any one of claims 119-144, wherein the crystalline Form III of celastrol comprises about 70 ppm or less of n-heptane.

147. The process, liquid formulation, amorphous solid dispersion, or pharmaceutical composition of any one of claims 119-145, wherein the crystalline form comprises about 5000 ppm or less of 2-methyltetrahydrofuran.

148. The process, liquid formulation, amorphous solid dispersion, or pharmaceutical composition of any one of claims 119-145, wherein the crystalline form comprises about 500 ppm or less of 2-methyltetrahydrofuran.

149. The process, liquid formulation, amorphous solid dispersion, or pharmaceutical composition of any one of claims 119-147, wherein the crystalline form comprises about 5000 ppm or less of ethyl acetate.

150. The process, liquid formulation, amorphous solid dispersion, or pharmaceutical composition of any one of claims 119-147, wherein the crystalline form comprises about 10 ppm or less of ethyl acetate.Attorney Docket No.: 045898-510001WO151. The process, liquid formulation, amorphous solid dispersion, or pharmaceutical composition of any one of claims 119-149, wherein the crystalline Form III of celastrol comprises about 3,000 ppm or less of methanol.

152. The process, liquid formulation, amorphous solid dispersion, or pharmaceutical composition of any one of claims 119-149, wherein the crystalline Form III of celastrol comprises about 1,500 ppm or less of methanol.

153. The process, liquid formulation, amorphous solid dispersion, or pharmaceutical composition of any one of claims 119-151, wherein the crystalline Form III of celastrol comprises about 5000 ppm or less of ethanol.

154. The process, liquid formulation, amorphous solid dispersion, or pharmaceutical composition of any one of claims 119-151, wherein the crystalline Form III of celastrol comprises about 600 ppm or less of ethanol.

155. The process, liquid formulation, amorphous solid dispersion, or pharmaceutical composition of any one of claims 119-154, wherein the crystalline Form III of celastrol is free of methanol, ethanol, and / or dichloromethane.

156. The process, liquid formulation, amorphous solid dispersion, or pharmaceutical composition of any one of claims 119-155, wherein the crystalline Form III of celastrol has at least 99.8% purity.

157. The process, liquid formulation, amorphous solid dispersion, or pharmaceutical composition of any one of claims 119-156, wherein the crystalline Form III of celastrol is anhydrous.